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The Role of galectin-3 in liver 















Liver progenitor cells (LPCs) respond to hepatic injury when hepatocyte division is 
impaired in chronic or severe injury. The LPCs are intimately surrounded by 
myofibroblasts, macrophages and laminin, thus constituting a potential progenitor 
cell niche. Laminin has been proposed to maintain LPCs in an undifferentiated state 
within the LPC niche. LPCs differentiate once they leave the laminin niche. However, 
mechanisms regulating this process have not been completely investigated. I 
hypothesized that cell membrane proteins which are implicated in intergin activation 
and mediation of cell adhesion to laminin such as galectin-3 and CD98 may be 
involved in this mechanism. Galectin-3 is a carbohydrate-binding protein which 
plays an important role in various cell functions, including cell growth, proliferation, 
adhesion, and differentiation. Galectin-3 has been reported to bind integrins and 
regulates β1 mediated adhesion to ECM. In addition, galectin-3 may also indirectly 
mediate β1 integrin activation by binding to and activating the heterodimeric 
transmembrane amino acid transporter CD98. However a role for galectin-3 in 
regulating LPC behavior has not been demonstrated.  
 
In this thesis, the mechanisms of galectin-3 mediating LPC proliferation and 
differentiation were investigated in an experimental model of LPC induction, the 
CDE diet, by using mutant mice lacking the gene encoding galectin-3. I have found 
galectin-3 is important for LPC induction and proliferation in vivo. In addition, 
galectin-3 is crucial for the LPC proliferation but is a negative regulator of LPC 
differentiation in vitro in a laminin dependent manner, suggesting that galectin-3 is 
required for LPC to maintain in an undifferentiated state on laminin. Moreover, the 
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extracellular binding activity of galectin-3 is important for LPC proliferation and 
adhesion to laminin. Furthermore, in the absence of galectin-3, LPCs down-regulate 
cyclin-D1 and the cyclin inhibitors p21 and p16 are elevated. Finally I suggest that 
integrin-β1 and CD98 are involved in regulating LPC proliferation.  
 
There is an increasing literature examining the role of LPC niche in regulating LPC 
behavior. My work suggests that galectin-3 is required for the expansion of LPCs in 
the injured adult liver. Galectin-3 enhances LPC adhesion to laminin. Galectin-3 is a 
crucial factor for LPCs to maintain in an undifferentiated state on laminin. My 
findings not only emphasize the requirement of LPCs to interact with their 
extracellular environment to expand but also propose that galectin-3 is a key 
signalling intermediary in the LPC niche, regulating homeostatic balance between 
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AIMS & HYPOTHESIS 
In this study, I hypothesize that galectin-3 can enhance LPC adhesion to laminin and 
plays an important role in LPC induction, proliferation, and differentiation. In 
addition, integrin activation and CD98 might be involved in regulating LPC 
proliferation. To investigate this hypothesis, I aim to examine the role of galectin-3 in 
LPC induction and proliferation in vivo by analyzing the galectin-3 null mice which 
were put on CDE diet, a model of LPC induction, for 12 days. In addition, I aim to 
isolate primary LPCs from galectin-3 null mice and knock down the expression of 
galectin-3 in LPC line: BMOLs to investigate the role of galectin-3 in LPC 
proliferation, differentiation and adhesion to laminin in vitro. Finally the mechanisms 
by which galectin-3 regulates LPC proliferation were investigated by examining the 
role of galectin-3 in regulating cell cycle regulators such as cyclin D1, p16, and p21. 
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1.2 Liver development and renewal 
 
1.2.1 Liver development  
 
During the embryo development, the endoderm germ layer is established during 
gastrulation and forms a primitive gut tube that is subdivided into foregut, midgut 
and hindgut regions (Figure 1.1 A). Liver arises from the foregut endoderm at 
embryonic day (ED) 8.5 and is engrafted by hematopoietic progenitor cells at ED9 to 
ED10. Only foregut endoderm is competent to develop into the liver (Fukuda-Taira, 
1981; Le Douarin, 1975; Okada, 1954); therefore, the establishment of the foregut 
progenitors is an important step in hepatogenesis. The expression of transcription 
factors such as Foxa2, Gata4–6 and haematopoetically expressed homeobox factor 
(Hex) have been shown to play important roles in early foregut organogenesis 
(Bossard et al., 1998; Bossard et al., 2000; Gualdi et al., 1996; Lee et al., 2005). In 
addition, the hepatic fate is induced by fibroblast growth factors (FGF) signals from 
the developing heart and bone morphogenetic proteins (BMPs) from the septum 
transversum mesenchyme (STM) (Fukuda-Taira et al., 1981; Gualdi et al., 1996; 
Jung et al., 1999; Le Douarin et al., 1975; Rossi et al., 2001). Moreover, Wnt and 
FGF4 signaling must be inhibited to maintain foregut identity and allow hepatic 
induction (Dessimoz et al., 2006; McLin et al., 2007; Wells and Melton, 2000), 
whereas becomes necessary to promote liver bud emergence and differentiation 
(McLin et al., 2007) (Zorn et al., 2008).  
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At ED 9.0, the hepatic diverticulum, an out-pocket of thickened ventral foregut 
epithelium adjacent to the developing heart, was formed (Figure 1.1B). This is the 
first morphological sign of the embryonic liver. The anterior portion of the hepatic 
diverticulum gives rise to the liver and intrahepatic biliary tree, while the posterior 
portion forms the gall bladder and extrahepatic bile ducts. Around ED 9.5, 
undifferentiated endodermal cells, known as hepatoblasts proliferate and then invade 
the adjacent STM to form the liver bud (Houssaint et al., 1980; Le Douarin et al., 
1975) (Zorn et al., 2008). A number of studies in mutant mice have shown that liver 
bud formation is tightly controlled by a network of transcription factors such as hex 
(Martinez Barbera et al.,2000; Bort et al., 2006), GATA-6 (Zhao et al., 2005), 
hepatocyte nuclear factor (HNF)-6 (Margagliotti et al., 2007), Onecut (OC)-2 
(Margagliotti et al., 2007), and prospero-related homeobox 1 (Prox-1) (Sosa-Pineda 
et al., 2000) 
 
Around ED 9.0- ED 9.5, the hepatoblasts start to express α-fetoprotein (αFP) 
followed by albumin then begin to express intermediate filament proteins (CK-14, 
CK-8, and CK-18), and γ-glutamyl transpeptidase (GGT) while proliferating (Brill et 
al., 1995; Tee et al., 1996) from ED 11. Hepatoblasts are bipotential and selectively 
differentiate into either hepatocytes or bile duct epithelial cells before ED16, which 
is a critical time to determine the fate of the desired lineage. This has been referred as 
the differentiation window during the hepatic development (Costa et al., 2003; Zaret 
et al., 2002; Lemaigre et al., 2003). The balance in the numbers of hepatocytes and 
cholangiocytes from hepatoblasts is achieved by integrated signalling and 
transcriptional networks. For example, both Notch and activin/TGF-β signaling 
pathway controls differentiation of hepatoblasts towards a biliary epithelial 
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phenotype (Kodama et al., 2004; Clotman et al., 2005 Clotman et al., 2006; 
Navarro-Alvarez et al., 2010), while HGF antagonises biliary differentiation and in 
conjunction with oncostatin M (OSM) promotes hepatocyte differentiation (Suzuki et 
al., 2003). In addition, Wnt signaling has been shown to play an important role in 
hepatic differentiation of fetal liver-derived LPCs or human embryonic stem cells 
(hESCs) (Hay et al., 2008; Bi et al., 2009). 
 
After ED 16, most of the hepatoblasts are committed to hepatocytic or cholangiocytic 
lineages. Thus they are no longer bipotential but still proliferating and become 
unipotent or late progenitor cells. Intrahepatic bile ducts are formed surrounding the 
large portal vein branches at ED 17. At this time point, the essential lobular 
arrangement of the liver is complete, but the maturation of the hepatic parenchyma is 
not complete until several weeks after birth (Van Eyken et al., 1998; 




















Figure 1.1 Liver development. (A) The cell lineage steps during hepatic 
development (red) (B) The schematic shows mouse embryos at different stages of 
development. Around ED 7-ED 8.5, the endoderm is patterned along the A-P axis 
into foregut (fg) midgut (mg) and hindgut (hg) progenitor domains. Hepatic fate 
specified in a portion of the ventral foregut endoderm adjacent to the heart at ED 8.5. 
The liver diverticulum (ld) forms by ED 9 and expands into an obvious liver bud (lb) 
by ED10. The liver grows, and by ED15 hepatoblasts are differentiating into 
hepatocyte and biliary cells. Final maturation of the liver is gradual and continues 
into the postnatal period. Picture copied from Zorn et al., 2008 
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1.1.2. Liver renewal 
 
The normal adult liver parenchyma consists of mitotically quiescent hepatocytes and 
cholangiocytes which are the epithelial cells of the bile duct and contribute to bile 
secretion via net release of bicarbonate and water. Both hepatocytes and 
cholangiocytes originate from a common endodermal foregut precursor cell. 
Hepatocytes which are fully differentiated cells generally have a very slow level of 
turnover. Remarkably, these cells have the ability to re-enter cell cycle in response to 
mitotic stimuli. Therefore, the adult healthy liver has a unique ability to restore its 
parenchymal mass and ensure the maintenance of multiple liver functions after 
different types of injury. Following hepatectomy or acute injury, the regeneration 
process occurs through the division of mature hepatic cell types, including 
hepatocytes, biliary epithelial cells, fenestrated endothelial cells, and Kupffer cells 
and contribute to the regeneration of hepatic tissue (Michalopoulos et al., 2007). 
 
In more severe liver injuries such as acute liver failure, cirrhosis and hepatocellular 
carcinoma when the function and proliferation of hepatocytes are impaired, liver 
transplantation is generally the best option to restore liver function. However, the 
number of donor organs is constantly insufficient to meet demand. Thus, alternative 
liver treatments are needed. There have been growing interests in LPCs as a potential 








1.2 Liver stem cells. 
 
1.2.1. Fetal liver stem/progenitor cells (FLSPCs) 
 
As mentioned previously, early fetal liver around ED 12–ED 16 contains 
hepatoblasts which are bipotent cells derived from endodermal cells. These cells are 
also known as fetal liver stem/progenitor cells (FLSPCs) due to their similar 
properties with liver stem/progenitor cells (Shafritz et al., 2006). They express dual 
markers of the hepatocyte and biliary lineages. In addition, they are capable of 
differentiating into either hepatocytes or biliary epithelial cells. This bipotent 
population is regarded as the fetal source of liver progenitor cells and may be useful 
for liver cell-based therapy. The successful isolation of FLSPCs depends on the liver 
developmental stages, since cells isolated in late embryological stages will lose the 
bipotent capacity and are not capable of differentiating into both lineages. 
 
Several markers have been found expressed by FLSPCs may be useful for isolation. 
Dlk (Tanimizu et al., 2003) and E-cadherin (Nitou et al., 2002) act as useful markers 
to enrich highly proliferative FLSPCs from fetal liver. Liv2, a hepatoblast marker 
and Prox1, a transcription factor expressed in early embryonic hepatoblasts, have 
been shown to be very important during liver development (Watanabe et al., 2002). 
Both Cd24a and Nope are cell surface markers that were shown to be expressed by 
murine FLSPCs (Nierhoff et al., 2003). In addition, it has been shown that Sall4 
regulates cell fate decision in fetal hepatic stem/progenitor cells not only by 
inhibiting their differentiation into hepatocytes but also by driving their 
differentiation toward cholangiocytes (Oikawa et al., 2009). 
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1.2.2. Liver progenitor cells (LPCs) 
LPCs, firstly described as “oval cells” in rodents and “intermediate hepatobiliary 
cells” in humans, are generally scarce in healthy liver but are stimulated when the 
regenerative capacity of hepatocyte is impaired. Numerous studies have indicated 
that when the replacement of hepatic mass loss by hepatocytes is partially or 
completely precluded, a distinct population of LPCs is induced to proliferate and 
differentiate towards hepatocytes (Lowes et al. 1999; Akhurst et al. 2001; Knight et 
al. 2005). Therefore, LPCs have been proposed as a “second line of defense” during 
liver regeneration. LPCs have also been proposed to arise from the intralobular bile 
ducts or from the “canals of Hering” which are the smallest, most proximal branches 
of the biliary tree (Akhurst et al., 2001; Factor et al., 1994; Knight et al., 2005).  
 
Extensive studies have been done to characterize LPCs due to their regenerative role 
in numerous liver diseases and their great potential for an alternative treatment to 
liver transplantation. Progenitor cells are also known as transit amplifying cells. They 
have the ability to proliferate rapidly and to generate more than one differentiated 
cell type (Potten et al., 1997; Shafritz et al., 2010). The first formal description of 
LPCs was reported by Farber in 1956. They found a population of nonparenchymal 
cells appearing in the rat liver after treatment with various carcinogenic agents and 
described them as “small oval cells with scanty lightly basophilic cytoplasm and pale 
blue-staining nuclei” (Farber 1956). LPCs have also been shown to represent a 
heterogeneous population of transit-amplifying progenitor cells ranging from an 
immature phenotype to mature cholangiocytes and intermediate hepatocytes. In 
addition, LPCs are bipotential progenitors capable of differentiation into mature 
hepatocytes and biliary epithelial cells that just like hepatoblasts can differentiate 
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into both lineages during fetal development (Shafritz et al., 2006).  
 
Many studies have been carried out to assess marker expression on LPCs. (Table1.1) 
LPCs have been reported to express the immature hepatocyte marker such as 
α-fetoprotein (αFP); the mature hepatocyte markers such as albumin, cytokeratin 
(CK 8) and CK18 , and the biliary epithelial cell markers such as γ-glutamyl 
transferase (GGT), CK7 and CK19 (Radaeva et al., 1995). In addition, LPCs also 
share some phenotypic characteristics with hematopoietic progenitor cells since they 
express the hematopoietic stem cell markers such as c-kit tyrosine kinase (c-kit), 
stem cell antigen-1 (Sca-1), CD34, and CD45 (Petersen et al., 2003, Crosby et al., 
2001). Recently, numerous studies suggested other new markers for LPCs such as 
Delta-like 1 protein (DLK 1) (Yovchev et al., 2007), epithelial cell adhesion 
molecule (EpCAM) (Okabe et al., 2009) or CD133 (Yovchev et al., 2006). However, 
universal and specific LPC markers have yet to be established. 
 
The localization of LPCs remains controversial; however, they have been identified 
in the periductular/ intraportal zone. In addition, they express some hematopoietic 
stem cell markers, including those found in the bone marrow side population. 
Therefore, LPCs have been suggested to arise from the bone marrow. Although some 
studies claimed that a portion of LPCs may arise from the bone marrow and is 
capable of differentiating into hepatocytes, (Petersen et al., 1999; Oh et al., 2007) 
many other studies indicated that mouse LPCs are not originated from the bone 
marrow but from the liver itself (Wang et al., 2003; Menthena et al., 2004). Moreover, 
a recent study has further confirmed that LPCs are not bone marrow derived in the 
CDE-fed mice (Lorenzini et al., 2010).  
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Table 1.1 Various markers expressed by adult liverprogenitor cells (Adapted from Bird et al., 2008) 
Adult biliary marker 
Cytokeratin 19 (CK19)  
CK7 
CK14 
γ-Glutamyl transpeptidase (γGT)  
Glutathione-S-transferase P (GST-P)  
Muscle pyruvate kinase (MPK)  
OV-6 (recognises CK14 and CK19) OV1  
A6  





Deleted in malignant brain tumour 
1 (DMBT1) 
 
Bisgaard et al. 1993 
Paku et al. 2005 
Bisgaard et al. 1993 
Cameron et al. 1978 
Tee et al. 1992 
Akhurst et al. 2005 
Bisgaard et al. 1993 
Sanchez et al. 2004 
Engelhardt et al. 1993 
Hixson and Allison 1985 
Zhang and Thorgeirsson 1994 
Yovchev et al. 2007 
Yovchev et al. 2007 
Yovchev et al. 2007 
Bisgaard et al. 2002 









Tian et al. 1997 
Libbrecht et al. 2000 
Libbrecht et al. 2000 
Gauldie et al. 1980 
Nagy et al. 1994 
Faris et al. 1991 
Hu et al. 1993 
Fetal hepatocyte markers 
α-Fetoprotein (αFP)  
Delta-like protein (dlk)  
Aldolase A and C  
c-Met  
Cadherin 22CD24  
CD44  






Evarts et al. 1987 
Yovchev et al. 2007 
Lamas et al. 1987 
Hu et al. 1993 
Yovchev et al. 2007 
Kon et al. 2006 
 
Fujio et al. 1994 
Zheng et al. 2006 
Omori et al. 1997 
Petersen et al. 2003 
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1.2.3. Small hepatocyte-like progenitor cells (SHPCs) 
 
Small hepatocyte-like progenitor cells (SHPCs), have also been described in the rat 
model of LPC induction- partial hepatectomy (PH) in combination with the treatment 
of pyrrolizidine alkaloid retrorsine (Gordon et al., 2000; Avril et al., 2004). It has 
been suggested that SHPCs may represent an intermediate or a transitional cell type 
between LPCs and mature hepatocytes rather than a distinct progenitor cell 
population (Fausto et al., 2004; Best et al., 2007). SHPCs have characteristics of not 
only mature adult hepatocytes but also fetal hepatoblasts and LPCs. They resemble 
differentiated hepatocyte to a certain degree since they express albumin and 
transferrin; generate bile canaliculi, and store glycogen, which are the functions of 
differentiated hepatocyte. However, early appearing SHPCs lack (or have reduced 
expression) of hepatic CYP proteins which is normally expressed on hepatocyte 
(Gordon et al., 2000). They also express the LPC and fetal liver cell markers: OC2, 
OC5, and AFP (Gordon et al., 2000). Moreover, they have high proliferative capacity 
in vitro and also following transplantation (Shibata et al., 2006), suggesting that they 
may have a role in repopulating the liver (Navarro-Alvarez et al., 2010). However, 
studies from the Forbes group have suggested that they are not an independent 
progenitor cell population but instead arise from LPCs (Vig et al., 2006). 
 
1.2.4. Animal models of LPC induction  
 
Among these different types of progenitor cells, LPCs have been widely investigated 
due to their great potential for future cell-based treatments of liver diseases. LPC 
proliferation can be induced in a number of ways. So far, a variety of liver injury 
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models to activate LPC proliferation have been established in rodents, including 
partial hepatectomy (PH) in combination with the treatment of a mitotic inhibitor 
such as 2-N-acetylaminoflourene (AAF) (Solt et al., 1977). Some toxins such as 
carbon tetrachloride (CCl4) and allyl alcohol have been used in combination with 
AAF to induce an LPC response (Petersen et al., 1999). However, the surgery is 
difficult to perform reproducibly in mice. Recently, choline-deficient diet 
supplemented with ethionine (CDE) (Akhurst et al., 2001) or the 3, 5- 
diethoxycarbonlyl-1, 4-dihydrochollinine (DDC) (Preisegger et al., 1999) diet 
models have become increasingly popular due to their efficacy. In these models, 
adult hepatocytes fail to respond to growth signals, leading to the activation and 
rapid proliferation of LPCs which have been described to appear near bile ductules 
initially and then migrate into the hepatic parenchyma.  
 
CDE diet has been widely used as a model to induce LPC activation. The CDE diet is 
effective, rapid, and does not require PH to generate substantial numbers of LPCs. 
The number of LPCs has been shown to increase significantly within 2 weeks 
(Akhurst et al., 2003). Notably, deregulated LPCs may be a potential source of liver 
cancer (Lee et al., 2006), with high incidence of hepatocellular carcinoma (HCC) 
observed in mice fed a choline-deficient diet containing 0.1% ethionine (CDE) for 19 
months (Yoshida et al., 1993). 
 
DDC diet is an alternative model to induce LPC activation in the mouse. It has been 
shown that feeding mice with DDC diet results in persistent proliferation of primitive 
ductules with poorly defined lumens (Preisegger et al., 1999). However, the precise 
the mechanism of activating LPCs in this model remains unknown. Similar to other 
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LPC induction models, DDC-induced atypical ductular proliferation (ADP) 
originated from the portal tract, spread into the hepatic lobule, and was associated 
closely with appearance of hepatocytes harboring an antigen (A6), which normally is 
expressed in biliary epithelium (Preisegger et al., 1999). Moreover, LPCs isolated 
from the DDC diet-fed mice have shown to repopulate hepatocytes in a 
transplantation model (Wang et al., 2003). 
 
 
1.2.5. LPC isolation and LPC line establishment  
 
An in vitro model is essential for further investigating the mechanisms controlling 
LPC behaviour. Several different techniques for isolating LPCs from rat have been 
shown recently (He et al., 2004; Pack et al., 1993; Tsao et al., 1984; Yasui et al., 1997; 
Yaswen et al., 1984). However, few studies have been conducted in mice 
(Fougere-Deschatrette et al., 2006; Li et al., 2006; Wang et al., 2003).  Percoll 
gradient centrifugation has been reported to successfully separate LPCs, hepatocytes 
and erythrocytes/ debris (Tirnitz-Parker et al., 2007). It has been commonly used as a 
method to isolate LPCs from the livers of CDE-fed mice. Generally, the 50% 
Percoll™ cell layer mainly consists of hepatocytes and the 20% Percoll™ cell layer 
consists of LPCs along with cells of similar size and density: primarily inflammatory 
cells and some other minor cell populations such as myofibroblasts and endothelial 
cells. The 20% Percoll™ layer of cells were collected and the CD45+ hematopoietic 
cells were depleted by using magnetic beads. Myofibroblasts usually attach to the 
plates later than LPC, thus they can be removed within 8 to 12 hours after the 
culturing of isolated LPCs by medium changing. In addition, endothelial cells can be 
removed by reducing the concentration of growth serum in the culture medium. The 
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established cultures were not pure but mainly consisted of LPCs (Tirnitz-Parker et al., 
2007). 
 
In order to get a purer population of LPCs, several antibodies have been tested to sort 
cells by flow cytometry and many sub-populations have been described as ‘LPCs’ in 
the literature. Numerous LPC surface markers have been identified (Santoni-Rugiu et 
al., 2005; Yovchev et al., 2007). For example, Ep-CAM, CD133, and DLK1 have 
been shown to express on the surface of LPCs (Yovchev et al., 2007; Okabe et al., 
2009). In addition, CD44 and CD24 which are cell membrane glycoprotein have 
been reported to express on LPC surface and can be used for isolation of LPCs (Kon 
et al. 2006; Yovchev et al., 2007). However, the research on identifying specific 
markers for a pure fraction of LPCs is still a major obstacle in LPC research. The 
reported markers are also frequently expressed in other cell types. In addition, few 
reported markers are surface proteins which are suitable for LPCs isolation by cell 
sorting. In addition, the numbers of different LPC populations are usually extremely 
low which makes LPC isolation difficult. Moreover, LPCs are heterogeneous and 
these cells change morphology and express different phenotypic markers when they 
differentiate (Yovchev et al., 2007).  
 
A variety of reports describing the establishment of biliary epithelial cultures, or the 
generation of LPC lines from rats have been published (He et al., 2004; Pack et al., 
1993; Tsao et al., 1984; Yasui et al., 1997; Yaswen et al., 1984). However, few 
studies have been conducted in mice (Fougere-Deschatrette et al., 2006; Li et al., 
2006; Wang et al., 2003). A recent study has established a LPC line: bipotential 
murine liver progenitor cells (BMOLs) from the livers of CDE-fed mice 
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(Tirnitz-Parker et al., 2007). They have demonstrated the establishment of highly 
enriched LPC cultures and the derivation of an immortalised, non-transformed, 
clonally derived LPC line from these cultures by using the “plate and wait” method 
developed for creation of embryonic liver progenitor cell lines (Strick-Marchand et 
al., 2002). In addition, they have indicated that the BMOLs express both hepatic and 
biliary markers, and exhibit biopotentiality, i.e. the ability to differentiate into both 
hepatic and biliary lineages in vitro.  
 
1.2.6. LPC differentiation  
 
LPCs play a critical role in the process of liver regeneration since these cells are 
capable of differentiating along the hepatic lineage into hepatocytes or 
cholangiocytes (bile duct cells). Several different protocols have been tried to 
differentiate primary LPCs to investigate the mechanisms governing LPC 
differentiation. Extracellular growth factors have been shown to be important for 
LPC differentiation. He et al. (2004) demonstrated that rat LPCs can differentiate 
into mature hepatocytes in the presence of epidermal growth factor (EGF) and 
hepatocyte growth factor (HGF) using a two-step induction protocol. Rat LPCs were 
cultured on a fibroblast feeder layer and supplemented with medium containing EGF 
for 6 days to induce the LPCs into small hepatocytes. A combination of HGF and 
EGF were then supplemented for another 6 days to differentiate them further to 
exhibit morphological, phenotypic and functional characteristics of hepatocytes (He 
et al., 2004). In addition, the second hepatic compartment: cholangiocytes were also 
differentiated from rat LPCs in their study. LPCs were grown on fibroblast feeders 
and HGF alone was supplemented in the medium for 6 days. Biliary epithelium was 
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classified based on the expression of CK19, and lack of expression of mature 
hepatocyte markers. In addition, it has been shown that treatment of the rat LPC line 
with oncostatin M (OSM) induced differentiation into hepatocytes (Okaya et al., 
2005). Moreover, the intracellular liver-enriched transcription factors 
CCAAT/enhancer binding protein α (C/EBPα) and hepatocyte nuclear factor 4α 
(HNF4α) have also been shown to be important in regulating LPC differentiation into 
hepatocytes (Dabeva et al., 1995; Nagy et al., 1994; Suetsugu et al., 2008).  
 
Few studies have been done to differentiate mouse LPCs into both lineages. Cultured 
LPCs in matrigel have been proved to favour biliary lineage differentiation (Li, et al., 
2002). In addition, Dimethyl sulfoxide (DMSO) has been identified to maintain 
hepatocyte differentiation phenotype in vitro (Spagnoli, et al., 1998). Li, et al (2006) 
have demonstrated that medium supplemented with 2 % matrigel and 2 % DMSO 
can differentiate mouse LPCs into both lineages. In addition, they also showed that 
culturing mouse LPCs on matrigel-coated plates with supplements of EGF can lead 
to murine LPC differentiation toward a hepatic fate, whereas supplementing the 
medium with HGF can lead to biliary lineage cell differentiation.  
  
It has been shown that LPCs can also differentiate into pancreatic cells or intestinal 
epithelium (Yang et al., 2002). However, LPCs may also have a pathological role 
since they have been implicated as precursors of hepatocellular carcinoma and 
cholangiocarinoma. (Sell et al., 1989) 
 
Notably, further in vivo research needs to be conducted to investigate LPC 
differentiation since other extracellular environmental factors may influence LPC 
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differentiation. Factors secreted by surrounding cells types, such as inflammatory, 
Kuppfer and hepatic stellate cells have also been proposed to play an important role 
in stimulating LPC proliferation and differentiation (Erker et al., 2008). Furthermore, 
hepatic stellate cells have been shown to induce differentiation of LPCs into mature 






















1.3 Liver progenitor cell (LPC) niche 
 
1.3.1. Location  
 
During embryonic development, hepatoblasts give rise to primitive intrahepatic bile 
ducts which connect parenchymal hepatocytes with the biliary system. These 
primitive intrahepatic bile ducts correspond to the canals of Hering and terminal bile 
ductules of adult livers may constitute the niche for LPCs (Van Eyken et al., 1998; 
Navarro-Alvarez et al., 2010). 
 
It is proposed that a restricted locale which is called “liver progenitor cell niche” 
surrounds LPCs and contributes to the support and regulation of LPC behaviour 
(Fuchs et al., 2004; Spradling et al., 2001). Within this niche, the direct contact 
between LPCs and supporting cells are thought to be responsible for maintaining the 
balance between progenitor cell expansion and differentiation (Nusse et al., 2008). 
This microenvironment comprises the extracellular matrix, epithelial and 
non-epithelial resident liver cells, recruited inflammatory cells, and a variety of 
growth-modulating molecules (Santoni-Rugiu et al., 2005). However, the precise 
location of the progenitor cell niche and the cellular components of this niche have 
not been well defined yet.  
 
1.3.2 Supporting cells in the LPC niche 
 
So far, several potential candidates in the LPC niche have been demonstrated, 
including macrophages, myofibroblast, endothelial cells, and hepatic stellate cells. It 
has been shown that LPCs are closely accompanied by a cellular niche composed of 
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macrophages, myofibroblast, and endothelial cells throughout the progenitor cell 
response in rodent models of LPC induction and human liver disease (Lorenzini et al., 
2010). 
 
In addition, hepatic stellate cells, portal fibroblasts, and myofibroblasts have been 
proposed to play an important role in constituting the LPC niche. Hepatic stellate 
cells have been demonstrated to have a close physical relationship with LPCs and 
also function as supporting cells in the niche, playing an important role in LPC 
expansion and differentiation (Roskams et al., 2008; Zhang et al., 2009; Braun et al., 
2003; Paku et al., 2001). Moreover, co-culture of hepatic stellate cells and LPCs cells 
results in increase in LPC proliferation and LPC differentiation into hepatocytes 
(Nagai et al., 2002; Lin et al., 2008; Deng et al., 2008). However, whether cell-cell 
contact is required for this mechanism remains unclear. Even so, soluble mediators 
produced by activated hepatic stellate cells have been suggested to mediate LPC 
proliferation (Santoni-Rugiu et al., 2005). Interestingly, quiescent hepatic stellate 
cells may have a counter effect that retains progenitor cells in the niche (Clouston et 
al., 2009). The stellate cells, which respond to liver injury through activation, may 
have different effects upon LPCs depending on liver activation status.  
 
The role of LPC neighbouring inflammatory cells in supporting LPC behaviour has 
also been proposed recently (Viebahn et al., 2008; Libbrecht et al., 2000; Viebahn et 
al., 2008). Recent studies also demonstrated that macrophages increased in number 
and surrounded around LPCs when LPC expansion was induced. Moreover, it has 
been shown that most of these macrophages are bone marrow derived (Lorenzini et 
al., 2010). Furthermore, cytokines produced by inflammatory cells such as the 
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tumour necrosis factor α (TNFα), interferon gamma (IFNγ), TNF-like weak inducer 
of apoptosis (TWEAK), lymphotoxin beta (LTβ), interleukin-6 (IL-6), and 
transforming growth factor beta (TGF-β) have been shown to be crucial for the LPC 
response (Knight et al., 2005; Viebahn et al., 2010). Viebahn et al. (2010) have 
shown that both infiltrating (CD11b+) and resident (CRIg+) macrophages are present 
around LPC response and these are the most important cytokine producers since they 
contribute to TNFα, IL-6, TGFβ and TWEAK. They proposed that liver macrophages 
in combination with these cytokines are important for the induction of LPC 
expansion. Moreover, they also proposed that during LPC response, LPCs 
themselves recruit macrophages to the damaged liver as LPCs express CCL2 and 
CX3CL1. Increased hepatic expression of chemokines such as CCL2 and CX3CL1 
were observed in LPC induction models, suggesting the role in mediating LPC 
response. It has been proved that CCL2 and CX3CL1 are expressed predominantly 
by infiltrating macrophages and crucial for attracting macrophages to the injured 
liver (Karlmark et al., 2008). Furthermore, they demonstrated that the LPC line: 
BMOLs can attract infiltrating (CD11b+) macrophages isolated from the livers of 
CDE-fed mice. More research is required to further analyze the role of macrophage 









1.3.3. The role of extracellular matrix in the LPC niche 
 
It has been proposed that cell-matrix and cell-cell interactions are important in 
regulating progenitor cell proliferation and differentiation within the LPC niche 
(Spradling et al. 2001). The basement membrane of bile ducts is composed of 
laminin and type IV collagen (Terada et al., 1994; Yasoshima et al., 2000). It is 
proposed that signals delivered by extracellular matrix (ECM) proteins, such as 
laminin and type IV collagen may also take part in regulating and supporting LPC 
behaviour. Previous studies have demonstrated that a laminin rich basement 
membrane is strongly associated with the LPC response in 2-acetylaminofluorene 
model of liver injury in rats (Paku et al., 2004). In addition, it has been found that 
laminin, but not type I and IV collagen was heavily deposited in sheath which closely 
surrounds LPCs in rodent models of LPC induction and human liver disease, while 
only appears prominently around portal vessel with weak staining in the control liver 
(Lorenzini et al., 2010). Interestingly, LPCs only extend as far as laminin sheath, 
suggesting the important role of laminin in constituting the LPC niche (Fig 1.2). 
 
Other research also indicated that LPCs appear partially differentiated when they are 
beyond the limit of the deposited laminin sheath (Van Hul et al., 2009), suggesting 
that a specialized matrix may be required for the expansion but not differentiation of 
LPCs. Laminin has been shown to facilitate LPCs to maintain an undifferentiated 
phenotype (Lorenzini et al., 2010). However, further research is required to 




1.3.4. The role of integrins in the LPC niche 
 
Integrins play an important role in mediating cell adhesion to a basal lamina. They 
have also been proposed as additional important factors in regulating LPC 
proliferation and differentiation within the LPC niche. Both neural stem cells and 
epidermal stem cells have been found to express high levels of integrin β1 (Campos 
et al., 2004; Jensen et al., 1999; Zhu et al., 1999). The niche may retain the 
progenitor cells by providing extracellular matrix (ECM) ligands for the integrin 
receptors on the surface of progenitor cells (Watt et al., 2000; Navarro-Alvarez et al., 
2010). Integrin α6β1 has been identified as a laminin receptor (Delwel. et al. 1996). 
Theoretically, the interaction between laminin and integrin α6β1 should be required 
to maintain LPCs in an undifferentiated state within the LPC niche. It has been 
shown that integrins (α2, α3, α5, α6, and α9, which dimerize with β1) and basement 
membrane components such as laminin and type IV collagen are predominantly 
expressed in human biliary epithelium (Yasoshima et al., 2000). Moreover, previous 
studies also examined the expression of integrin CD49f (integrin 6α) in 
non-parenchymal cell fraction isolated from normal human, acutely injured and 
chronically injured liver. They have found that the proportion of cells expressing the 
integrin 6α was higher in diseased liver than in normal liver, suggesting a possible 
but unproven role of integrin 6α in LPC expansion (Laurson et al., 2007). However, 
little research has been carried out to investigate the expression of integrins in rodent 
models of LPC induction. Unpublished studies from the Forbes group (Clayton) have 
demonstrated different expression level of integrin subunits during the differentiation 
of LPCs into hepatocytes. The expression of integrin β1 increases when LPCs 
differentiate into biliary progenitor cells and when they differentiate into to mature 
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hepatocytes, they begin to express integrin α1β3. These findings suggested that 
integrins may be essential for cell differentiation decision of the LPCs. Clearly, 
further research has to be done to analyze the role of integrins in regulating LPC 


































Figure 1.2 Heptic progenitor cell niche It has been proposed that laminin and other 
supporting cells such as macrophages and myofribroblast might be essential 
component of the LPC niche to regulate LPC proliferation and differentiation. 
Laminin might be required to maintain LPCs in an undifferentiated state within the 



















1.4.1 General Backgrounds 
Galectins, widely distributed in mammals, birds, amphibians, fish, nematodes, 
sponges, and some fungi, contain a carbohydrate-recognition domains (CRD) which 
is a beta-sheet and consists of about 130 amino acids.  Galectins are a family of 
proteins defined by having at least one characteristic carbohydrate recognition 
domain (CRD) with an affinity for beta-galactosides through a conserved sequence in 
the carbohydrate-binding site (Barondes et al., 1994). The CRD of galectins is 
responsible for carbohydrate binding and is able to recognize various carbohydrates 
attached to proteins and lipids on cell surfaces and extracellular matrices, known as 
glycoconjugates. Galectins have many intra- and extracellular functions through 
glycoconjugate-mediated recognition, varying from the regulation of cell adhesion 
and promotion of cell–cell interactions. 
 
1.4.2 The galectin family 
 
Fifteen mammalian galectins have been identified and classified into three groups 
according to their biochemical structure (Hirabayashi et al., 1993). The Prototype 
galectins (galectin-1.-2.-5.-7.-10.-11.-13.-14 and -15) consist of one CRD and a short 
N-terminal sequence; they normally exist as monomers or non-covalent homodimers 
(Fig 1.2 A). The Tandem repeat type of galectins (galectin-4,-6,-8,-9, and-12) contain 
two non-identical CRDs linked via a short peptide sequence up to 70 amino acids 
(Fig 1.2 B). The Chimera type of galectin (galectin-3) consists of one CRD and one 
non-lectin domain contains unusual tandem repeats of short amino-acid stretches 




Figure 1.3 Galectin Family (A) The Chimera type galectins cross-link one CRD and 
a non lectin– domain. (B) Some prototype galectins present as dimers, crosslinking 















Generally, galectins are either bivalent or multivalent according to their 
carbohydrate-binding activities. Some Prototype galectins (One-CRD) are found as 
dimers. Tandem repeat types of galectins (Two-CRDs) consist of two carbohydrate 
binding sites, and galectin-3 normally forms oligomers when it binds to multivalent 
carbohydrates. The CRD of galectins can recognize adjacent oligosaccharides and 
different galectins can bind to different sets of oligosaccharides. Galectins have been 
found to crosslink cell-surface glycoconjugates and trigger a cascade of 
transmembrane signalling events which are important for apoptosis and cell-cycle 
progression. In addition, galectins can cause the clustering of multiple multivalent 
glycoconjugates which results in a lattice formation.  
 
Although there is no evidence of a signal sequence in galectins, which is required for 
protein secretion through the classical secretory pathway, some galectins have been 
found in the extracellular space and secreted by cells, probably through a 
non-classical secretory pathway (Cooper et al., 1990; Hughes et al., 1999). 
Galectin-3 can also relocalize to the plasma membrane and then become a part of 
vesicles which extrude from the plasma membrane, but the signals which control this 
are still unknown (Liu et al., 2002). 
 
Galectins have been found widely distributed in various tissues or specific to certain 
types of tissue. The expression of galectins have been found to be regulated during 
the development and altered under different physiological or pathological conditions 






1.5.1 Structure   
 
Galectin-3 , a 30 kDa unique chimeric gene product, consists of three structural 
domains: (A) a NH2-terminal domain of 12 amino acid that contains a serine 
phosphorylation site; (B) a repeated collagen-like sequence rich in glycine, proline, 
and tyrosine; and (C) a COOH-terminal carbohydrate recognition domain (CRD) 
consisting 140 amino acid residues (Figure 1. 4).  
 
As all galectins, galectin-3 is composed of a carbohydrate-recognition-binding 
domain (CRD) about 130 amino acids that enable specific binding of β-galactosides 
(Liu. et al., 1990; Hughes et al., 1994; Barondes et al., 1994). The C-terminal domain 
of galectin-3, within the carbohydrate-recognition domain includes NWGR; this 
motif is highly conserved within the BH1 domain of the Bcl-2 family proteins, and it 
was shown to be responsible for the anti-apoptotic activity of both Bcl-2 and 
galectin-3 (Yang et al., 1996). (Fig. 1.4) 
 
The N-terminal domain (ND) of galectin-3 is composed of 110–130 amino acids. 
This domain is involved in the oligomerization of galectin-3. The oligomerization 
results in the formation of a galectin- 3 molecule that possesses multivalent CRDs 
and enables galectin -3 to mediate crosslinking of its ligands (Barondes et al., 1994, 
Kasai et al., 1996, Hughes et al., 1997). The ND has been also implicated in secretion 
of galectin-3 outside of cells (Menon et al., 1999). Deletion of these first 11 amino 
acids (following the first methionine) blocks secretion of galectin-3 (Gong et al., 
1999). In addition, the phosphorylation at the position Ser6 of galectin-3 strongly 
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affects its sugar binding affinity (Mazurek et al., 2000). Moreover, the presence of 
both phosphorylated and unphosphorylated form of galectin-3 has been reported for 
the first time in murine 3T3 fibroblasts; phosphorylated galectin-3 was found in both 
the cytoplasm and the nucleus, whereas unphosphorylated form was found 
exclusively in the cytoplasm (Cowles et al., 1990). These findings suggested 






















Figure 1.4 Structure and functional domain of galectin-3 picture copied from 

















1.5.2 Distribution and basic function 
 
Galectin-3 has been found in various types of cells, including epithelial cells, 
fibroblasts, dendritic cells, and inflammatory cells (Flotte et al., 1983). In particular, 
galectin-3 is highly expressed on activated macrophages and monocytes (Liu et al., 
1995). The expression of galectin-3 has been found to correlate with cancer 
aggressiveness and metastasis (Takenaka et al., 2004; Iurisci et al., 2000; Buttery et 
al., 2004; Kim et al., 1999). For example, galectin-3 has been found expressed in 
thyroid, breast, and colon carcinoma (Xu et al., 1995; Castronovo et al., 1996; 
Schoeppner et al., 1995). The over-expression of galectin-3 has been reported in 
hepatocellular carcinoma. In addition, galectin-3 is involved in the tumour 
progression and related to the biomarker for tumor development and could be the 
prognosis of hepatocellular carcinoma which suggests that galectin-3 can be used as 
a potential therapeutic target (Matsuda et al., 2008).  
 
Galectin-3 has been reported to be involved in various biological phenomena, 
including cell growth and proliferation (Moutsatsos et al., 1987; Inohara et al., 1998), 
adhesion (Kuwabara and Liu, 1996; Inohara and Raz, 1995; Inohara et al., 1996), 
cell survival (Yang et al., 1996; Akahani et al., 1997), and cell cycle control (Kim et 
al., 1999; Lin et al., 2000). 
 
Galectin-3 can be found on the cell surface, extracellularly and intracellularly, and in 
both the cytoplasm and nucleus. The nuclear localization of galectin-3 is well 
documented; however, the well-characterized nuclear localization signal and the 
mechanism by which the protein is sequestered in nuclei remain unknown. It has 
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been suggested that galectin-3 shuttles between the cytoplasm and nucleus on the 
basis of targeting signals that are recognized by importin(s) for nuclear localization 
and exportin-1 (CRM1) for nuclear export. 
 
Gong et al. reported that the first eleven residues of galectin-3 governed its nuclear 
import (Gong et al., 1999); however, later study rather implied the involvement of 
the CRD in nuclear import and retention of galectin-3 inside the nuclei (Spector et al., 
2001). Moreover, Nakahara et al. identified a sequence in residues 223-228 
(HRVKKL) of galectin-3, within CRD, is similar to the lysine/arginine-rich nuclear 
localization signal (NLS) which is found in many nuclear proteins. Furthermore, 
galectin-3 has been shown to bind to importin-αdirectly (et al., 2006).  
 
Galectin-3 export is rapid and selective process that proceeds via leptomycin (LMB) 
- inhibitable pathway (Tsay et al., 1999). The addition of LMB which is a drug 
shown to bind to and inhibits the interaction of exportin-1 (CRM1) with leucine-rich 
NESs contributes to the retention of galectin-3 in the nucleus. The NES (residues 
241-256) is found in the hydrophobic β-sandwich motif of the CRD and is highly 
conserved in the galectin-3 homologues of various species. On the other hand, it was 
found that only phosphorylated galectin-3 is transported out of nuclei (Tsay et al., 
1999). Mutant at the position ser6 of ND which is the major site of phosphorylation 
inhibit galectin-3 exported from the nucleus to cytoplasm, suggesting that 





1.5.3. Intracellular functions of galectin-3 
 
Intracellular galectin-3 has been found shuttling between nucleus and cytoplasm 
(Davidson et al., 2002) and engaged in various basic cellular functions such as 
pre-mRNA splicing, cell growth, cell apoptosis, and cell-cycle regulation (Dagher et 
al., 1995; Vyakamam et al., 1997; Wang et al., 2004). Several proteins have been 
shown to interact with galectin-3 such as Bcl-2 (Yang et al., 1996; Akahani et al., 
1997), Gemin4 (Park et al., 2001), Ras (Elad-Sfadia et al., 2004), Akt/PKB (Oka et 
al., 20055), and β–catenin (Shimura et al., 2004) have been identified. 
 
Galectin-3 has been identified to have a similar sequence to B cell lymphoma 2 
(BCL2), which is a suppressor of apoptosis (Yang et al., 1996). Galectin-3 and BCL2 
both contain an Asp-Trp-Gly-Arg (NWGR) motif in the carboxyl- terminal part of 
the molecule which is a sequence essential for the regulation of apoptosis. Generally, 
substitution of glycine to alanine in this motif stimulates the anti-apoptotic activity of 
galectin-3 (Akahani et al., 1997). However, the motif in galectin-3 functions has not 
been completely investigated. Moreover, the direct interactions between these two 
proteins and their intracellular associations have also not been established. However, 
it has been proposed that galectin-3 has a regulatory role in anti- apoptosis by 
binding to BCL2 or mediating the transport of BCL2 to mitochondria (Liu et al., 
2002).  
 
Galectin-3 has been shown to interact with Gemin4 which is a component of a 
macromolecular complex involved in pre-mRNA splicing. This suggests the role of 
galectin-3 in the splicing pathway (Park et al., 2001). 
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Galectin-3 has been found interacting with oncogenic Ras, especially KRAS (Paz et 
al., 2001; Elad-Sfadia et al., 2004). These interactions promote Ras-mediated signal 
transduction such as RAF1, extracellular signal-regulated kinase (ERK) 1/2, 
phosphatidylinositol-3-kinase (PI3K) and the serine/threonine kinase Akt, which play 
essential roles in cell proliferation, differentiation, survival, and death (Elad-Sfadia et 
al., 2004).  
 
Galectin-3 has been shown to be involved in Wnt/β-catenin signalling. Galectin-3 
can bind to β-catenin, which is the effector component of Wnt signalling pathway. 
Phosphorylation of casein kinase I (CKI) and glycogen synthase kinase 3β (GSK3β) 
result in activation of β-catenin. Galectin-3 has been found to co-localize β-catenin in 
the cell nucleus and stimulate cyclin D1 or c-myc expression which are important for 
cell cycle regulation and promoting cell cycle progression (Shimura et al., 2004; 
Shimura et al., 2005).  
 
1.5.4. Extracellular functions of galectin-3 
 
Galectin-3 has also been found to be present on the cell surface and in the 
extracellular compartment. The biological activities of extracellular galectin-3 
mainly involve its interactions with various β-galactoside containing glycans via 
CRD. Galectin-3 can bind to cell-surface glycoconjugates that contain 
galactose-containing oligosaccharides. Inhibitors of galectin-3 that function in the 
extracellular compartment have been identified, eg. lactose (Platt et al., 1992; 
Inohara et al., 1994; Pienta et al., 1995). Various glycoproteins such as laminin 
(Ochieng et al., 1995; Wang et al., 1992; Kuwabara et al., 1996), collagen IV 
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(Ochieng et al., 1998), fibronectin (Matarrese et al., 2000; Sato et al., 1992), hensin 
(Hikita et al., 2000), and elastin (Ochieng et al., 1999) have been shown as 
extracellular receptors for galectin-3. In addition, integrin α1β1 (Ochieng et al., 1998; 
Andre et al., 1999) and CD98, a transmembrane protein which will be introduced 
later, have also been proved as important ligands for galectin-3 (Dong et al., 1996).  
 
Galectin-3 has been found to play a key role in modulating cell to cell, and cell to 
extracellular matrix interaction. Furthermore, it is now proposed as a mediator of 
signal transduction events on the cell surface which is summarized in Figure 1.5. 
Galectin-3, as other receptor-ligand systems, can cross link surface glygoproteins and 
transduce signals to regulate gene expression (Ochieng et al., 2004). Galectin-3 is 
also involved in regulating a variety of extracellular processes such as kidney 
development, angiogenesis, neuronal functions, tumor metastasis, autoimmune 
disorders, endocytosis and possibly exocytosis (Bao et al., 1995; Liu et al., 1993; Raz 













Figure. 1.5. The extracellular functions of galectin-3. Red arrows indicate positive 
effects. AGE: advanced glycation end products, C4.4A: the GPI-anchored 
glycoprotein C4.4A, CEA: carcinoembryonic antigen, EGFR: epidermal growth 
factor receptor, L1: neural adhesion molecule L1, Lamp 1/2: lysosome associated 
membrane protein 1/2, LPS: lipopolysaccharide, Mac-2BP; Mac-2 binding protein, 
MAG: myelin associated glycoprotein, N-CAM: neural cell adhesion molecule, 
NCA-160: non-specific crossreacting antigen 160, NG2: the transmembrane 
chondroitin sulfate proteoglycan NG2, TβR: transforming growth factor β receptor, 




1.5.5. The regulating role of galectin-3 in cell adhesion 
 
Galectin-3 regulates cell-cell and cell-matrix adhesive interactions, which are crucial 
for normal cellular motility and polarity and during tissue formation. It has been 
shown that epithelial cells, which lack galectin-3 expression, interact poorly with 
their extracellular matrices. In addition, it has been demonstrated that galectin-3 is 
related to several disease states such as tumour progression. For example, the 
migration of human metastatic breast tumour cell-lines through a Matrigel barrier in 
a Transwell assay was increased by a moderate sub-micromolar concentration of 
galectin-3 (Le et al., 1996). Moreover, galectin-3 may regulate cell growth by 
mediating cell adhesion. For example, it has been shown that galectin-3 promotes 
neural cell adhesion on laminin and neurite growth (Penka et al., 1998).  
 
Generally, galectin-3 can modulate cell adhesion on extracellular matrix either 
positively or negatively. For example, breast cancer cells with high expression of 
galectin-3 interact well and spread very rapidly on ECM proteins compared to those 
with low or no galectin-3 expression (Warfield et al., 1997; Matarrese et al., 2000; 
Honjo et al., 2001). Galectin-3 significantly increased the adhesion of human 
neutrophils to various substrata (Ohannesian et al., 1994; Kuwabara et al., 1996). 
However, galectin-3 has been shown to reduce the adhesion of myoblasts and kidney 
epithelial cells to laminin (Sato et al., 1992). 
 
A model of cell adhesion regulated by galectin-3 has been proposed by Hughes 
(Hughes et al., 2001). Galectin-3 may modulate cell adhesion through either direct or 
indirect effects which involves integrin activation. (Figure 1.6) The regulation of cell 
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adhesion by galectin-3 may be positive or negative. Monovalent galectin-3 may 
ligate with glycoproteins of either an integrin or extracellular matrix protein, thus 
weakening the adhesive interaction by steric hindrance. (Fig. 1.6 A) On the other 
hand, a functionally bivalent galectin-3 can also act synergistically on cell-cell 
adhesions and cell-matrix adhesions to stimulate adhesion by cross-linking 
cell-surface and matrix molecules (Fig. 1.6 B) (Hughes et al., 2001). This mechanism 
may also involve integrin activation. Galectin-3 may regulate integrin activation 
which is essential for cell adhesion to ECM by binding to the extracellular domains 



















Figure 1.6 Galectin-3 might modulate cell adhesion by regulate adhesive 
potential between cell-cell or cell-matrix positively or negatively. (A) Monovalent 
Galectin-3 binds to either integrin or laminin, thus weakening the adhesive 
interaction by steric hindrance. (B)Bivalent Galectin-3 can act synergistically in 
cell-cell or cellmatrix adhesion, thus stimulate adhesion. Picture adapted from the 





1.5.6. Galectin-3 plays a regulatory role in cell growth and cell cycle regulation 
 
The role of galectin-3 in regulating cell growth has been demonstrated by numerous 
studies. For example, transfecting the human T lymphoma Jurkat cells with 
galectin-3 can lead to faster cell growth than control transfectants not expressing 
galectin-3, especially under suboptimal growth condition (Yang et al., 1996). 
Furthermore, transfecting the human breast cancer cells with antisense galectin-3 
cDNA significantly decreased cell proliferation (Van den Brule et al., 1997). 
Moreover, it has also been indicated that galectin-3 transfectants of Jurkat cells 
mentioned above can survive significantly longer than control transfectants when 
they were treated with anti-Fas receptor antibody which can cross-links Fas receptor 
and causes apoptosis (Yang et al., 1996). Also, overexpression of galectin-3 in human 
breast carcinoma cells inhibited apoptosis (Akakani et al., 1997). These findings 
suggested the function of galectin-3 in either promoting cell growth or inhibiting cell 
death. 
 
Nonetheless, the mechanism of galectin-3 regulation of cell growth has not been 
completely investigated. As mentioned above, intracellular galectin-3 has been found 
to bind components such as Bcl-2 and Ras to regulate cell apoptosis and cell 
proliferation. For example, it has been shown that galectin-3 can stimulate 
proliferation of rat hepatic stellate cells through the MEK1/2 - ERK1/2 signaling 
pathways (Maeda et al., 2003).  On the other hand, it is also possible that 
extracellular mechanisms are involved. Galectin-3 may regulate cell growth by 
binding cell surface glycoconjugates to modulate cell adhesion on extracellular 
matrix. It has also been shown that adding galectin-3 exogenously can stimulate 
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growth of fibroblasts (Inohara et al., 1998), mesangial cells (Sasaki et al., 1999), and 
promote outgrowth of neurites from dorsal root ganglia explants (Pesheva et al., 
1998). 
 
Cell proliferation is known to be controlled by cell cycle regulators. For example, 
Cyclin D1 forms a complex with and functions as a regulatory subunit of CDK4 or 
CDK6, whose activity is required for G1 to S cell cycle transition. It has been shown 
that cyclin D1 interacts with retinoblasma tumour suppressor protein (Rb) and the 
expression of this gene is regulated positively by Rb. P21 (WAF1), a potent 
cyclin-dependent kinase inhibitor (CKI) which binds and inhibits the activity of 
cyclin E/CDK2 and cyclin D/CDK4 complexes directly functions as a regulator of 
cell cycle progression from G1 to S phase. The expression of p21 is controlled by the 
tumour suppressor protein p53 and cell growth arrest by p21 can promote cellular 
differentiation. Moreover, p16, Cyclin-dependent kinase inhibitor 2A, is a tumour 
suppressor protein which plays an important role in regulating cell cycle. P16 
functions as a cell cycle G1 control through the regulatory roles of CDK4 and p53 in 
cell cycle G1 progression. Mutations in p16 increase the risk of developing multiple 
cancers, thus p16 is known to be an important tumour suppressor gene. It has been 
demonstrated that increased p16 gene expression reduces the proliferation of stem 
cells (Krishnamurthy et al., 2006). (Figure 1.7) 
 
The role of galectin-3 in regulating the expression of cell cycle regulators has also 
been demonstrated. Galectin-3 has been shown to activate the cyclin D1 promoter in 
human breast epithelial cells (Lin et al., 2002). In addition, galectin-3 knockdown in 
human prostate cancer cells led to cell-cycle arrest at G1 phase, up-regulation of p21, 
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Figure 1.7 Cell cycle regulated by cyclins and cell cycle inhibitors. copied from 














and hypophosphorylation of the retinoblasma tumor supressor protein (pRb) (Wang. 
et al., 2009). Moreover, galectin-3 binds to β-catenin which is an intracellular protein 
implicated in cell cycle regulation and colocalizes with β-catenin in the nucleus to 
stimulate gene expression of cyclin D1 and c-myc which are important for cell cycle 
progression (Shimura et al., 2004).  
 
The mechanism by which galectin-3 regulates cyclin D1 remains unclear. It is 
believed that the activation of the cyclin D1 promotor can be triggered by growth 
factors targeting several signal transduction pathways such as the 
Ras-Raf-p42/p44MAPK (Albanese et al., 1995; Lavoie et al., 1996; Lee et al., 1999). 
The growth factor activation of cyclin D1 promoter is mediated by multiple binding 
sites on the cyclin D1 promoter (Guttridge et al., 1999; Hinz et al., 1999; Joyce et al., 
1999; Matsumura et al., 1999; Nagata et al., 2001; Watanabe et al., 1996). On the 
other hand, cell adhesion signalling has been proved to be required for cyclin D1 
transcription (Le Gall et al., 1998; Zhu et al., 1996). It has been shown that cell 
adhesion-mediated cyclin D1 promoter activation appears to occur through focal 
adhesion kinase (FAK) (Zhao et al., 1998) and integrin-linked kinase (ILK) pathways 
(D'Amico et al., 2000). However, it has been demonstrated that galectin-3 induces 
cyclin D1 promoter activity in human breast epithelial cells independent of cell 
adhesion. They proposed that galectin-3 may be involved in the 
enhancement/stabilization of nuclear protein-DNA complex formation at the CRE 





1.5.7. The role on galectin-3 in liver biology 
Little research on the function of galectin-3 in the physiologic and pathologic 
processes of liver has been published (Henderson et al., 2006; Shimonishi et al., 2001; 
Kristensen et al., 2000; Hsu et al., 1999; Santucci et al., 2000). Galectin-3 expression 
has been found to increase significantly in the regenerative nodules of cirrhotic liver 
tissues and during hepatocellular carcinoma (Hsu et al., 1999). In addition, inhibition 
of galectin-3 on the surface of cancer cells results in reduced cell attachment to 
laminin and metastasis in the liver (Inufusa et al., 2001). 
 
The role of galectin-3 in modulating the growth of hepatic stellate cells has been 
proposed. Galectin-3 has been found to modulate the growth of fibroblasts by 
interacting with their surface glycoconjugates (Inohara et al., 1998). Furthermore, it 
has been shown that galectin-3 can stimulate proliferation of rat hepatic stellate cells 
through the MEK1/2 - ERK1/2 signaling pathway (Maeda et al., 2003). 
 
The role of galectin-3 in liver fibrosis has also been demonstrated. It has been shown 
that the expression of galectin-3 was significantly up-regulated in stellate cells when 
they transdifferentiate into myofibroblasts, a process called "self-activation" (Maeda 
et al., 2003). In addition, previous studies showed that disruption of the galectin-3 
gene blocks myofibroblast activation and significantly attenuated liver fibrosis 
(Henderson et al., 2006). Furthermore, in vivo siRNA knockdown of galectin-3 
inhibited myofibroblast activation after hepatic injury may therefore provide an 
alternative therapeutic approach to the prevention and treatment of liver fibrosis 





1.6.1 Structure and basic functions  
 
Integrins are a family of cell surface receptors for extracellular matrix ligands or 
cell-surface ligands, and mediate mechanical and chemical signal from the cell 
surface (Giancotti. et al. 1999). Integrins are transmembrane heterodimers which 
contain two distinct chains- α (alpha) and β (beta) subunits. The integrin family is 
composed of at least 24 heterodimers assembled from 18 alpha and 8 beta subunits. 
Integrin subunits span the plasma membrane. Generally, integrins have very short 
cytoplasmic domains of about 40–70 amino acids. Extracellulary, the alpha and beta 
chains lie closely together and form a ligand-binding region for the extracellular 
matrix. Integrins bind to extracellular matrix proteins such as collagen, laminin, and 
fibronectin. Integrin α1β1, α2β1, α3β1, α6β1, α7β1, and α6β4 have been shown to be 
laminin receptors (Delwel. et al. 1996).  
 
1.6.2 Integrin signalling pathways 
 
Integrins generate intracellular signals either by binding extracellular ligand 
(outside-in signalling) or by regulating cytoplasmic signals within the cell (inside-out 
signalling) (Hynes et al., 2002). Integrin signalling plays an essential role in 
regulating cell physiology, including morphology, adhesion, survival or apoptosis, 
shape, polarity, motility, proliferation, and differentiation. It is proposed that several 
integrins are expressed on the cell surface in an inactive state and require cellular 
activation with a variety of agonists to acquire the capability to mediate adhesion to 
their appropriate ligands (Dustin. et al.1991, Shaw. et al. 1990, Shaw. et al. 1993).  
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Integrins regulate a variety of signalling pathways such as FAK, PI3K, PKB/Akt, and 
RAS/ERK pathways which are involved in cell proliferation and cell survival. For 
example, cellular adhesion through integrins results in phosphorylation of FAK then 
activates PI3K kinase which provides protective signal acting through PKB/Akt to 
block entry into cell apoptosis (Khwaia et al., 1997). In addition, the action of 
RAS/ERK pathway has been shown to promote cell cycle progression and crucial for 
cell proliferation (Marshall et al., 1995). (Figure 1.8) 
 
 
Figure 1.8 Integrin signaling pathway  Figure shows major signaling pathways 
that are known (solid arrows) or presumed (dashed arrows) to be coordinately 






1.7.1 Structure and basic function 
CD98, a multifunctional membrane protein originally discovered on the surface of 
activated T cells, is now known to be present in many cell types and all malignant 
cell lines (Haynes et al., 1981, Deves et al., 2000). CD98 was initially characterized 
as a T-cell activation marker, and was later shown to function as an amino-acid 
transporter (Nakamura et al., 1999). 
 
The CD98 family is composed of widely expressed cell-surface disulfide-linked 
125-kDa heterodimeric membrane glycoprotein which contains a common 
glycosylated 80-kDa heavy chain (CD98hc, 4F2hc, SLC3A2) and a group of 
45-kDa light chains (Mastroberardino et al., 1998, Hemler et al., 1982) (Fig 1.9). In 
this heterodimeric form, the CD98 protein transfers specific groups of amino acids 
across the plasma membrane. The determination of group and mechanism depends 
on the properties of the specific light chain. Various light chains have the potential to 
form a complex with heavy chain depending on the cell type and intracellular 
localization (Nakamura et al., 1999; Dalton. et al., 2007). CD98 has been implicated 
in a variety of functions including amino acid transport, cell survival, integrin 
activation, and cell fusion (Warren et al., 1999; Fenczik et al., 1997; Ohgimoto et al., 
1995). 
 
1.7.2 The role of CD98 in cell growth and tumorigenesis 
 
It has been shown that CD98 is rapidly up-regulated early in the transition from G0 
to G1 phase following cellular activation and remains elevated until the cell cycle is 
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complete (Azzarone et al., 1985; Suomalainen et al., 1986; Parmacek. et al.1989). In 
addition, CD98hc is highly expressed on the surface of tumour cells and it is widely 
believed that CD98hc plays an important role in tumorigenesis (Bellone et al., 1989; 
Dixon et al., 1990). For example, CD98hc overexpression leads to 























Figure 1.9 Model of CD98 structure. The heterodimer CD98 consist of a 
glycosylated heavy chain and a group of light chain. The two type of subunits are 











1.8 The interactions of galectin-3 with Integrins / CD98 
Galectin-3, a proposed ligand for the glycosylated extracellular domain of CD98hc, 
is one of the candidates of CD98 natural activators (Dalton1et al., 2007). Galectin-3 
has been reported to bind integrin α1β1 (Ochieng et al., 1999) and up-regulate 
integrin expression (Le et al., 1996). Moreover, exogenous galectin-3 can enhance 
the adhesion of platelets to immobilized fibrinogen or fibronectin by mediating 
integrin α2β1 or α5β1, respectively (Fujimoto et al., 2000).  
 
Numerous studies have indicated that CD98 is strongly associated with integrin 
activation. It has been proposed that the cytoplasmic domain of CD98 intracellularly 
binds to the cytoplasmic tail of specific integrin β-subunits and promotes integrin 
activation through incompletely identified intracellular signalling pathways (Hughes 
et al., 2001). For example, integrin-mediated adhesion of human cancer cell lines to 
fibronectin or laminin was up-regulated by ligation of surface-expressed CD98 with 
the 4F2 antibody (Fenczik et al., 1997; Chandrasekaran et al., 1999). In addition, the 
4F2 antibody also induces T-cell proliferation in a integrin-dependent manner 
(Warren et al., 2000).  
 
Moreover, several studies indicated that CD98 plays significant roles in regulating 
integrin-mediated functions such as cell proliferation, survival, adhesion and 
apoptosis. For examples, CD98 clustering can activate Rap1, a Ras-related 
GTP-binding protein, and increase the affinity of integrin α5β1 to activate the PI3K 
signaling pathway (Fujimoto et al., 2000). CD98hc is required for efficient 
adhesion-induced activation of Akt and Rac which are involved in cell survival and 
cell migration in ES cells (Feral et al., 2005). In addition, cross-linking CD98 with 
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4F2 antibody stimulates integrin-mediated increases in focal adhesion kinase (FAK) 
and PI3K activation (Henderson, 2004). 
 
Galectin-3 has been demonstrated to promote CD98 dimerization and integrin 
activation. It has been proposed that the association of CD98 and integrin subunits 
requires dimerization of CD98 and this is mediated by galectin-3. Galectin-3, an 
endogenous cross-linker of CD98, can ligate the glycosylated extracellular domain of 
CD98, thus mediate integrin clustering on the surface of cells to increase the avidity 
of binding (Hughes et al., 2001). This mechanism may mediate cell adhesion to 
extracellular matrix such as laminin. However, it still remains unclear whether 
galectin-3 can trigger CD98 mediated-integrin activation (Figure 1.10).  
 
The purpose of my research project was to evaluated the role of galectin-3, CD98, 
and integrin in regulating LPC induction, proliferation and differentiation which to 













Figure 1.10 Galectin-3 might mediate CD98 dimerization which promotes 
integrin activation and cell adhesion to laminin. Picture adapted from the review 











1.9 Aims and hypothesis 
 
In this study I hypothesize that galectin-3 can enhance LPCs adhesion to laminin and 
plays an important role in regulating LPC induction, proliferation, and differentiation. 
In addition, integrin activation and CD98 may be involved in regulating LPC 
behaviour. 
 
To investigate this hypothesis, the following aims were established 
 
1. To investigate the expression of galectin-3 in the livers of CDE-fed mice. 
Firstly, the expression of galectin-3 in the livers of CDE-fed mice was assessed to 
investigate whether the expression of galectin-3 was strongly associated with LPC 
activation. 
 
2. To investigate the function of galectin-3 in LPC induction and proliferation in 
vivo. 
The function of galectin-3 in LPC induction was then investigated by using 
galectin-3 null mice. These mice were put on the CDE diet for 12 days to 
investigate the role of galectin-3 in LPC induction.  
 
3. To investigate the role of galectin-3 in LPC proliferation and differentiation in 
vitro 
Next, the role of galectin-3 in regulating LPC proliferation and differentiation in 
vitro was assessed by isolating primary LPCs from the livers of the CDE-fed WT 
and galectin-3 null mice. The expression of galectin-3 on primary LPCs was 
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analyzed and the proliferation and differentiation assay were then conducted on 
isolated primary WT and galectin-3 null LPCs.  
 
4. To confirm the role of galectin-3 in LPC differentiation in vitro by knocking down 
galectin-3 expression. 
The role of galectin-3 in LPC differentiation into both hepatic and biliary lineages 
was confirmed by knocking down the expression of galectin-3 in LPC line: 
BMOLs. Galectin-3 siRNA was transfected into BMOLs and the effect of 
knocking down galectin-3 expression on LPC differentiation into both lineages 
was then analyzed.   
 
5. To investigate the role of laminin in LPC differentiation in vitro 
  The role of laminin in LPC differentiation was also investigated by culturing 
BMOLs on laminin-coated or plastic plates under the condition which promote 
differentiation.   
 
6. To investigate the role of the extracellular binding activity of galectin-3 in LPC 
proliferation and adhesion to laminin. 
   The extracellular binding activity of galectin-3 was blocked by treating BMOLs 
with lactose, the competitive inhibitor of galectin-3. Then the effect of lactose on 
LPC proliferation and adhesion was assessed by the MTT proliferation assay and 
adhesion assay.  
 
7. To investigate the mechanism of galectin-3 regulating LPC proliferation. 
   The role of galectin-3 in regulating the expression of cell cycle regulators and 
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cell-adhesion mediated signalling pathway was then assessed in galectin-3 null 
primary LPCs and galectin-3 siRNA transfected BMOLs  
 
8. To investigate the expression of CD98 and integrin β1 in the livers of CDE-fed 
mice and primary LPCs. 
   To analyze whether CD98 and integrin β1 are involved in regulating LPC 
behaviour, their expression were investigated in the livers of CDE-fed WT and 
galectin-3 null mice and primary LPC culture. However, the precise regulatory 
roles of CD98 and integrin β1 in LPC induction, proliferation, and differentiation 

















Chapter 2  
 
Material and Methods 
 
2.1 Galectin-3 null mice  
 
Galectin-3 null mice were generously given by Professor Tariq Sethi. Generation of 
galectin-3 null mice by gene targeting technology has been described previously. 
(Colnot et al., 1998) Homologous recombination removes exons II, III, and IV, 
including the initiating codon in exon II in galectin-3. As controls, age- and sex- 
matched WT C57/B6 mice were used. All animal work was carried out under 
procedural and ethical guidelines of the Home Office (UK). 
 
2.2 Animal model of LPC induction: Choline-Deficient, Ethionine-Supplemented 
(CDE diet) 
 
CDE diet, a rodent model of LPC activation, was used to assess the cellular 
constituents of the liver tissue niche. In the dietary protocol of LPC induction, age- 
and sex- matched C57/B6 and galectin-3 null mice were fed a diet composed of 
powdered choline deficient chow (MP biomed) supplemented with DLethionine 
(Sigma) at 0.15% in sweeten water: Robson orange juice (to improve animal 
tolerance to ethionine) for 12 days.  
 
After 12 days, both C57/B6 and galectin-3 null mice were sacrificed and the liver 
tissues were harvested. The liver tissue was either incubated in 10% of formalin for 6 
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hours or in Methcarn (6% of Methanol, 1% of Acetic Acid, and 3% of chloroform) 
overnight. The liver tissues were then washed with 70% ethanol and embedded with 
paraffin.   
 
2.3 Immunohistochemistry (IHC) 
 
3.5μm-thick paraffin embedded sections were dewaxed and rehydrated prior to IHC. 
The following are different antigen retrieval methods for different antibodies. The 
sections were microwaved in 10 mM sodium citrate buffer (pH 6.0) for 5 min then 
incubated with proteinase K at 37℃ for 5 min (12.5 % in PBS) (Sigma, UK) 
(PanCK). The sections were microwaved in 10 mM sodium citrate buffer (pH 6.0) 
for 20 min then microwaved in Tris buffer EDTA (PH9.0) for 20 min (CD98, 
galectin-3). The sections were incubated with trypsin (0.01% in 0.1% CaCl2) at 37 .℃  
for 15 min (VWF). The sections were microwaved in Tris buffer EDTA (PH9.0) for 
20 min (Desmin) or 10 min (Integrinβ1). The sections were microwaved in 10 mM 
sodium citrate buffer (pH 6.0) for 10 min (Ki67). There is no antigen retrieval 
required for Laminin and F4/80 staining.  
 
After the antigen retrieval, the tissue was washed with PBS for 5 min then incubated 
with 3% hydrogen peroxide for 10 minutes (Sigma, UK) to block the endogenous 
peroxidase. After washing with PBS, the liver sections were treated with an 
avidin/biotin kit (Vector Lab ®) to block all endogenous biotin, biotin receptors, or 
avidin binding sites present in tissues prior to the addition of the labeled avidin 
reagent. To block nonspecific binding, the tissue sections were incubated with 20% 
serum (either normal swine, or rabbit serum) for 30 minutes at room temperature. 
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The tissue sections were then incubated with specific primary antibodies diluted in 
serum at appropriate dilution for 1 hr. After washing with PBS, biotinylated 
secondary antibodies were then incubated for 30 minutes followed by a tertiary layer 
of avidin/biotin peroxidase (R.T.U Vectastain Kit, Vector Lab.®) for 30 minutes at 
room temperature then 3,3’diaminobenzidine (DAB; DAKO®) was applied to the 
sections for 5 minutes. The sections were counterstained with hematoxylin, 
dehydrated, cleared in xylene, and coverslipped. 
 
For the Desmin staining, the Vector® M.O.M. ™ (Mouse on Mouse) 
immunodetection kits which are designed specifically to localize mouse primary 
monoclonal antibodies on mouse tissues were used according to the manufacturer’s 
guideline. After the liver sections were treated with an avidin/biotin kit (Vector Lab 
®) for 15 minutes, M.O.M. ™ Mouse Ig Blocking Reagent was incubated with liver 
sectons for 1 hour. After washing with PBS, the tissue sections were incubated with 
M.O.M. ™ Diluent for 5 minutes. Desmin antibody was the diluted in M.O.M. ™ 
Diluent to 1:50 and incubated with the sections for 30 minutes. After washing with 
PBS, M.O.M. ™ Biotinylated Anti-Mouse IgG Reagent was incubated with sections 
for 10 minutes. A tertiary layer of avidin/biotin peroxidase (R.T.U Vectastain Kit, 
Vector Lab.®) was then applied for 30 minutes at room temperature then 
3,3’diaminobenzidine (DAB; DAKO®) was incubated with the sections for 5 
minutes. The sections were counterstained with hematoxylin, dehydrated, cleared in 




Table 2.1 The primary and secondary antibodies used for this study 
Primary antibodies Host animal Source (Catalogue number) Dilution 
Anti -Pancytokeratin Rabbit DAKO 1:200 
Anti -F4/80    Rat eBioscience 1:300 
Anti - Desmin  Mouse DAKO 1:50 
Anti - VWF Rabbit DAKO 1:50  
Anti- galectin-3    Rat (Fitc- 
conjugated)
Cedarlan Lab Limit 
1:200 
Anti- CD98 Goat Santa Cruz 1:200 
Anti- Ki67 Rat DAKO 1:50 
Anti- laminin Rabbit DAKO 1:200 
Anti- Integrinβ1 Rabbit DAKO 1:50 
Secondary antibodies Host animal Source Dilution 
swine anti-rabbit Swine DAKO 1:400 
Rabbit anti Rat Rabbit DAKO 1:400 
Rabbit anti - FITC Rabbit DAKO 1:4000 




Immunofluorescence was conducted for the double immunostaining of panCK and 
Ki67; PanCK and galectin-3; PanCK and CD98. 3.5μm-thick paraffin embedded 
sections were dewaxed and rehydrated. For antigen retrieval, the sections were 
microwaved in 10 mM sodium citrate buffer (pH 6.0) for 10 min. To block 
nonspecific binding, the tissue sections were incubated with 20% donkey serum for 
30 minutes at room temperature. The tissue sections were incubated with specific 
 70
primary antibodies (Ki67, galectin-3, or CD98) diluted in donkey serum at 
appropriate dilution overnight. After washed with PBS Tween (0.1%) three times, the 
tissue was then incubated with secondary antibodies for 30 minutes at room 
temperature. The sections were washed with PBS Tween (0.1%) three times then 
incubated with with 20% donkey or goat serum for 30 min. The sections were then 
incubated with Anti-PanCK antibody for 1 hr. After washing steps, the sections were 
incubated with secondary antibodies for 30 minutes at room temperature. After 
washed with PBS in rocker, the sections were then mounted with vector shield 
(containing DAPI) and the slide was sealed with nail varnish. The antibodies used for 
the study were listed below. 
 
Table 2.2 The primary and secondary antibodies used for this study 
Primary antibodies Host animal Source (Catalogue number) Dilution 
Anti -Pancytokeratin Rabbit DAKO 1:200 
Anti- galectin-3    Rat (Fitc- 
conjugated)
Cedarlan Lab Limit 
1:200 
Anti- CD98 Goat Santa Cruz 1:200 
Anti- Ki67 Rat DAKO 1:50 
Secondary antibodies Host animal Source Dilution 
Anti-rabbit Alexa 488 Donkey Invitrogen 1:250 
Anti-rabbit Alexa 568  Goat Invitrogen 1:250 
Anti- goat  Alexa 546 Donkey Invitrogen 1:250 






Cultured cells were seeded overnight onto the 12-well plate in normal culture 
conditions. Primary LPCs were fixed with methanol for 20 min then washed with 
PBS then blocked with 5% normal goat, or donkey serum in PBS for 30 min. Cells 
were then incubated with primary antibodies in 1% bovine serum albumin (BSA) in 
PBS for 1hr. Cells were then washed three times with PBS and incubated with 
secondary antibodies in PBS in darkness for 30min at RT. After three more washes, 
cells were mounted with with DAPI (Vector Lab. ®). The antibodies used for the 
study were listed below. 
 
Table 2.3 The primary and secondary antibodies used for this study 
Primary antibodies Host animal Source (Catalogue number) Dilution 
Anti-CD29(integrin-β1) Hamster BD Science 1:100 
Anti -Pancytokeratin  Rabbit DAKO 1:100 
Anti- CD98 Goat Santa Cruz 1:200 
Anti – galectin-3 Rat Cedarlan Lab Limit 1:100 
Secondary antibodies Host animal Source Dilution 
Anti-hamster Alexa 568 Goat Invitrogen 1:250 
Anti-rabbit  Alexa 488 Donkey Invitrogen 1:250 
Anti-rabbit  Alexa 568 Goat Invitrogen 1:250 
Anti- goat  Alexa 546 Donkey Invitrogen 1:250 





2.6 LPCs counting 
 
2.6.1 PanCK positive LPCs counting 
 
40 consecutive non overlapping high power (x20) fields from each animal were 
counted. LPCs were recognized by the small (approximately 10μm) oval/cuboidal 
morphology with high nuclear to cytoplasmic ratio. Cells with hepatocyte like 
morphology (larger (over 20μm) with low nuclear to cytoplasmic ratio) were not 
counted even if they have weak staining for panCK. Interlobular bile ducts defined as 
cells small panCK positive cells directly abutting a lumen were excluded. 
 
2.6.2 Ki67 and PanCK double positive LPCs counting 
 
10 non overlapping high power (x20) field pictures from each animal were taken. 
Ki67 (Red) nuclear positive cells with PanCK membrane positive (Green) cells were 
counted. PanCK positive (Green) cells with blue Dapi nuclear staining were also 
counted. The ratio of Ki67 and PanCK double positive cells to PanCK positive cells 
was then calculated.  
 
2.7 Primary LPC (Liver Progenitor Cells) isolation and culture. 
 
LPCs were isolated from WT and galectin-3 null mice. 5 weeks old mice were 
treated with the CDE diet plus 0.15% ethionine in sweetened water for 12 days. The 
liver was chopped into small pieces then incubated with L15 Medium (Sigma), 
50ug/ml DNase 1 (Roche), and 250ug/ml Collagenase typeV (Sigma) at 37 ℃ in 
shaking incubator for 45 min. Liver cells were then strained through a 40um filter 
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into a 50ml falcon followed by three times of spinning at 50g for 1 min to pellet out 
hepatocytes and large clumps of cells. After lysing haemocytes with lysis buffer on 
ice for 5 min, cells were then resuspended in LPC Complete Medium: 45% DMEM 
High Glucose (PAA), 45% Ham’s F10 Medium (PAA) 10% FBS (Hyclone), 1ug/ml 
Insulin (sigma), 50ug/ml Hydrocortisone (Sigma), 50ug/ml Gentamycin (PAA), 2.5 
ml Sodium Pyruvate (PAA). LPCs were then purified by centrifugation through a 
discontinuous gradient of 20 and 50% Percoll™ (Sigma) in PBS at 1400 × g for 
20 min at 4℃. The lower layer was collected separately and washed twice with PBS. 
Cells were then resuspended in 1X BD imag buffer (BD). Fc Blocks (0.25ug/106 
cells) was then incubated with cells for 15 min on ice. Cells were then incubated with 
Rat anti Mouse CD45R/B220 (BD, 50ul/107 cells) at 6~12℃ for 30 min. After bring 
the volume up to 1-8 x 107 cells/ml with 1x BD imag buffer, tube was then 
immediately placed on magnet for 6-8 minutes. Supernatant which contained the 
CD45- cells were then collected. The positive fraction off the side of the tube was 
then washed with 1ml of 1X BD imag buffer and the tube was replaced on the 
magnet for 5 min. The negative fraction was collected again and then washed with 
PBS and resuspended in LPC Medium with 10% serum. To reduce fibroblast 
contamination, cells were gently washed 8–12 h after plating to remove non-adherent 
cells. Cells were cultured in a humidified atmosphere with 95% O2 / 5% CO2 at 
37 °C. To reduce endothelial growth in the cultures, LPC Medium with 5% serum 
was the replaced after 2-3 days. 
 
2.8 BMOL (Bipotential Murine Lliver Progenitor Cells) 
 
BMOL cell line was generously given by Dr. Belinda Knight. They were established 
from primary LPC cultures which were isolated from the liver of CDE treated mice 
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using a technique called “plate and wait” (Strick-Marchand and Weiss, 2002).  
 
Primary LPC cultures were maintained in growth-promoting conditions for several 
weeks until the cultures reached senescence and the majority of cells died and lifted 
off the plate. A small number of surviving epithelioid cells formed small colonies and 
these colonies were expanded, replated at low density and clonally derived cell lines 
established. Cells were passaged weekly until the cell lines became stable, displaying 
consistent morphology and growth.( Tirnitz-Parker et al.,2007) 
 
BMOLs were cultured with 5% FBS (PAA), 2mM L-glutamine (PAA), 10U/ml 
Penicillin; 100ug/ml Streptomycin(PAA), 30ng/ml IGF2 (Invitrogen), 20ng/ml EGF 
(Sigma) and 10ug/ml insulin (Sigma). Cells were cultured in a humidified 
atmosphere with 95% O2 / 5% CO2 at 37 °C 
 
2.9 LPC differentiation in vitro 
 
For primary LPCs differentiation, 1ml matrigel (R&D) was thawed at 4°C overnight 
then suspended in 50 ml LPC Medium supplement with 10% FBS to get 
homogeneous 2% Matrigel medium. 2% matrigel medium which was supplemented 
with 50 ng/ml epithelial growth factor (EGF) (Sigma) was then added to the cells. 
After 1, 3, 5 days of induction, cells were fixed with methanol for staining or the 
total RNA was extracted from the cells.  
 
For BMOL cell differentiation, 1ml matrigel (R&D) was thawed at 4°C overnight 
then suspended in 50 ml BMOL cell Medium supplement with 10% FBS (without 
IGF2) to get homogeneous 2% Matrigel medium. 2% matrigel medium which was 
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supplemented with 50ng/ml EGF (Sigma) and 30ng/ml human recombinant 
oncostatin M (OSM) (Roche) was then added to the cells. After 1, 3, 5 days of 
induction, cells were fixed with methanol for staining or the total RNA was extracted 
from the cells.  
 
2.10 siRNA transfection 
 
Transfection with Hiperfect (Qiagen) was performed according to the manufactures’s 
protocol. The day before transfection, 1 x 105 / well cells were seeded in a 12-well 
plate in 0.1 ml of BMOL culture medium containing serum and antibiotics and 
cultured under normal growth conditions. 75 ng of galectin-3 siRNA was added in 
100 µl culture medium without serum (this will give a final siRNA concentration of 
10 nM) and the reagent was mixed by vortexing. 6 µl of HiPerFect was then added in 
Transfection Reagent to the diluted siRNA and the reagent was mixed by pipetting 
up and down 5 times. Transfection Reagent was then incubated for 5–10 min at room 
temperature (15–25°C) to allow formation of transfection complexes. The complexes 
were then added drop-wise onto the cells. The plate was gently swirled to ensure 
uniform distribution of the transfection complexes. Cells were incubated with the 
transfection complexes under their normal growth conditions. After 3 h, 400 µl of 
BMOL culture medium was added into cells. 
 
Four siRNA against mouse galectin-3 and scrambled siRNA use as a negative control 
were purchased from Qiagen. Upon receipt 10nmol lyophilized siRNA was 
resuspended in 100μl sterile, RNase-free water to each tube to obtaina 10μM 
solution. The followings are target sequences for the four different galectin-3 siRNA. 
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Table 2.4 The target sequence for four galectin-3 siRNA used for this study 
siRNA Target sequence 
Mm_Lgal3_1 (sequence 1) AACTATGTAATTATCAATAAA 
Mm_Lgal3_2 (sequence 2) CAGGAGAGTCATTGTGTGTAA 
Mm_Lgal3_3(sequence 3) CACAATCATGGGCACAGTGAA 
Mm_Lgal3_4 (sequence 4) CTGCTCGTGACTGCTAGGCAA. 
 
 
2.11 Quantitative real-time RT-PCR analysis 
 
2.11.1 Total RNA extraction 
 
Total RNA from cultured cells was extracted using RNeasy ® Mini Kit (Qiagen) 
according to manufacturer’s instructions. For cell lines: The cell culture medium was 
removed and rinsed by PBS. 250 µl of RLT buffer was added to a culture dish and 
the cells were harvested by cell scraper (Corning) and transferred into a QIAshredder 
spin column (Qiagen), followed by centrifugation at 13,000 rpm for 2 minutes. An 
equal volume of 70% ethanol was added to the homogenized lysate. After mixing 
well by pipetting, the mixture was transferred to an RNeasy spin column and 
centrifuged for 15 seconds at 10,000 rpm. 700 µl of buffer RW1 was added to the 
column and the column was centrifuged for 15 seconds. Next the column was 
washed twice with 500 µl of RPE buffer, followed by centrifuging for 1 minute. 
Finally, 30 µl of the RNase-free water was added to elute the RNA. The 
concentration of RNA was then determined by NanoDrop. (Thermo) 
 
For extracting RNA from the liver tissue, less than 30 mg of liver tissue was placed 
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into 1.5 ml eppendorf. The tissues was disrupted and homogenized by the vessel in 
RLT buffer containing ß-ME and then the mixture was transferred into a 
QIAshredder spin column, following by centrifugation at 13,000 rpm for 2 minutes. 
An equal volume of 70% ethanol was added to the homogenized lysate. After mixing 
well by pipetting, 700 µl of the mixture was transferred to an RNeasy spin colum and 
centrifuged for 15 seconds at 10,000 rpm. 700 µl of buffer RW1 was added to the 
column and the column was centrifuged for 15 seconds. Next the column was 
washed twice with 500 µl of RPE buffer, followed by centrifuging for 1 minute. 
Finally, 30 µl of the RNase-free water was added to elute the RNA. The 
concentration of RNA was then determined by NanoDrop. (Thermo) 
 
2.11.2 Reverse Transcription 
 
Riverse Transcription was performed by using QuantiTect Rev. Transcription Kit 
(Qiagen) in 20 μl reactions. RNase inhibitor and dNTPs are already included in the 
kit components. gDNA Wipeout Buffer was used to eliminate Genomic DNA 
contamination in RNA samples. The following represent one reverse transcription 
reaction: 
 
One Reaction mix: 
RNA                 1 μg 
gDNA Wipeout Buffer   2 μl 
RNAse-free water      variable 
Total volume          14 μl 
 
This mixture was incubated at 42˚C for 2 minutes to eliminate Genomic DNA 
contamination in RNA samples and then placed on ice for over 1 minute. Then the 
following reaction mix was prepared and added previous mixture .  
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One Reaction mix: 
5X Quantiscript RT Buffer (contains Mg2+ and dNTPs) 4 μl 
RT Primer Mix                                 1 μl 
Quantiscript Reverse Transcriptase                 1 μl 
 
 
The total 20 μl of mixture was mixed by pipetting gently and then incubated at 50˚C 
for 30 minutes and then 95˚C for 3 minutes to inactivate Quantiscript Reverse 
Transcriptase. The cDNA was then ready to serve as template for quantitative PCR 
(qPCR) reaction.  
 
2.11.3 Quantification of mRNA using real-time PCR 
 
qPCR was performed using the QuantiTect SYBR Green PCR Kit (Qiagen) 
QuantiTect Primers used in qPCR reactions were purchased from Qiagen (Table 2.5) 
The following volumes represent one PCR reaction: 
 
1x Reaction mix 
2x Quantifast SYBR Green PCR master mix          12.5 µl  
10x QuantiTect Primers                            2.5 µl             
cDNA templates (dilute 1 in 200 from 1µg of cDNA)     10 µl  
Total volume                                     25 µl 
 
Reaction was then transferred into MicroAmp® Optical 96-Well Reaction Plate 
(Applied Biosystems). qPCR reactions were performed by the following steps: 
Pre-incubation at 95˚C for 5 minutes for PCR initial activation step, denaturation at 
95˚C for 10 seconds, combined annealing and extension at 60˚C for 30 seconds, the 
last two steps were repeated for 35 cycles. Primers were purchased from Qiagen. The 
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following primers were used for SYBR Green real-time RT-PCR 
 
Table 2.5 The primers used for SYBR Green real-time RT-PCR 
Gene Catalog number 
Peptidylprolyl isomerase A: Mm_PPIA_1_SG QuantiTect Primer  
Assay Qiagen (Cat. No. QT00247709) 
Albumin Mm_Alb_1_SG QuantiTect Primer 
Assay Qiagen (Cat. No. QT00115570) 
Aquaporin-1 Mm_Aqp1_1_SG QuantiTect Primer 
Assay Qiagen (Cat. No. QT00109242) 
Gamma-glutamyl transpeptidase(GGT) Mm_Ggt1_1_SG QuantiTect Primer 
Assay Qiagen (Cat. No. QT00104209) 
Cytokeratin 19(CK19) Mm_Krt19_1_SG QuantiTect Primer 
Assay Qiagen (Cat. No. QT00156667) 
Alpha-fetoprotein (AFP) Mm_Afp_1_SG QuantiTect Primer  
Assay Qiagen (Cat. No. QT00174020) 
Cytokeratin 7(CK7): Mm_Krt7_1_SG QuantiTect Primer 
Assay Qiagen (Cat No. QT00173649 
Delta-like 1 (DLK 1) Mm_Dlk1_1_SG QuantiTect Primer  
Assay Qiagen (Cat. No. QT00134344) 
Hepatocyte Nuclear Factor 4(HNF4) Mm_Hnf4a_1_SG QuantiTect Primer 
Assay Qiagen (Cat. No. QT00144739) 
Galectin-3 Mm_Lgals3_1_SG QuantiTect Primer  
Assay Qiagen (Cat. No. QT00152558) 












2.12 Sodium dodecedyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blotting 
 
2.12.1 Preparation of protein from cells 
 
Medium was removed and the cells were rinsed with ice cold PBS. 100 μl of ice cold 
lysis buffer with protease inhibitors (1:100 PMSF, 1:500 Aprotinin, 1:500 Levpeptin, 
1:100 Benzunidine, and 1:100 Orthovaradate) was added into a well of 12 well plate 
(35 mm culture dish) and cells were scraped on ice and the cell lysate was transferred 
to a 1.5 ml eppendorf. The cell lysate was then sonicated 5 times (2 seconds 
sonication with 5 second rest intervals). To remove the debris, the tube was 
centrifuged at 13,000 rpm for 10 minutes at 4˚C, and the supernatant was collected and 
stored at -20˚C until required.  
 
2.12.2 Bradford assay and protein sample preparation.  
 
Protein content was quantified by using Bradford assay. The sequential dilution of the 
standards was prepared as 5, 2.5, 1.25, 0.625, 0.3125, 0.15625, 0.078125 μg/μl of 
BSA. 5μl of each dilution of the standard and protein samples was added into a 96 
well plate, in triplicate. The Bradford reagent was prepared (75μl H2O + 75μl 
Bradford for each sample) and 150 μl prepared mixture was then added to each wells. 
The plate was then read at 595 nm on microplate reader. The figure of the 
concentration of protein standards vs. OD was the plotted to determine protein 
concentrations of unknown from the standard curve. 10 μg of protein was then added 
with 5x Lemmli and then boiled for 10 minutes at 95˚C for SDS-PAGE gel.    
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2.12.3 SDS-PAGE gel  
 
The glass plates and gel holder were cleaned thoroughly and the glass plates were 
inserted into the gel holder. The upper gel was added into glass plates quickly after 
the lower gel was added. The comb was then placed in and the gel was left for 30 
min. Then the gel was placed in the holder and 1x running buffer was filled up. The 
individual well was washed by needles. Both standards and samples were loaded and 
then gel was run at 90V until the samples reached the end of gel.   
 
2.12.4 Transfer Blotting 
 
The SDS-PAGE gel was assembled in the transfer cassette with the order of 
(negative anode pole) - sponge / Whatman blotting paper / PAGE / nitrocellulose 
membrane (Whatman) / Whatman blotting paper / sponge - (positive cathode pole). 
The transfer cassette was placed in a transfer tank with transfer buffer and the 
transfer was performed at 300 mA for 1hours at 4˚C.  
 
After transfer, the nitrocellulose membrane was left air dry for 30 min then stained 
by Ponceau-S (0.2% Ponceau-S in 3% trichloroacetic acid) to check the efficiency of 
transfer. The membrane was then washed by TBST several times and blocked in 5% 
skimmed milk powder solution (prepared in TBST) for 1 hour at room temperature. 
The membrane was incubated with antibodies at appropriate dilutions (in 5% milk or 
5% BSA in TBST) for 1 hour at room temperature or overnight at 4˚C. To remove 
excess antibody, the membrane was washed by TBST for 3 times, 5 minutes each. 
The membrane was incubated with horseradish peroxidase-linked (HRP) secondary 
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antibody (1:2000 in 5% skimmed milk or BSA / TBST) for 1 hr at RT. The 
immune-signal was detected by using chemiluminescent HRP substrate kit (Millipore) 
according to the manufacturer’s instructions (GE Healthcare, RPN2106) and 
developed in a Medical Xray Fijifilm (Fisher). 
 
The antibodies used in this study were listed in below table. 
 
Table 2.6 The list of the primary and secondary antibodies 
Primary Antibody Host animal Source  Dilution 
Anti-actin Rabbit Santa cruze 1:1000  
Anti-phospho-FAK Rabbit Cell Signaling 1:1000 
Anti-AKT Rabbit Cell Signaling  1:1000 
Anti-Phospho-AKT  Rabbit Cell Signaling  1:1000 
Anti-Phospho-ERK Rabbit Cell Signaling  1:1000 
Anti-FAK Rabbit Cell Signaling 1:1000 
β-catenin Mouse Millipore 1:500 
Anti-Phospho-GSK3 Rabbit Cell Signaling 1:1000  
Anti-cyclinD Mouse Cell Signaling 1:1000 
Secondary antibodies Host animal Source (Catalogue number) Dilution 
Anti-mouse HRP Horse Cell signaling 1:2000 






2.12.5 Stripping nitrocellulose membranes  
 
A nitrocellulose membrane can be re-used for another immunological detection. 
Previous immune-complexes were removed by incubating the membrane in stripping 
solution for 15 minutes at 60˚C. The membrane was washed 4 times with TBST, 










1.5g TrisBase, 5g SDS, 250mg Bromphenolblue(0.05%), 25ml Glycerol, 5ml 
Mercaptoethanol, made up to 20ml H20  
 
Lower Gel  
 
Lower gel stock was made from 40ml lower gel buffer (90.8 g Tris Base, 2g SDS, 
made up to 500ml H2O PH 6.8), 36ml Glycerol, 64ml Acrlamide, and 20ml H20, 
 




Upper gel stock was made from 50ml upper gel buffer (30g Tris Base, 2g SDS, made 
up to 500ml H2O PH 9.8) , 32ml Acrlamide and 118ml H20 
 




10x running buffer: 
 
10g SDS, 144g Glycin 30.3 g Tris Base, made up to 1L H2O 
 
10x Transfer buffer: 
 








100 mM β-mercaptoethanol, 2% SDS and 50 mM Tris-HCl  pH6.7 
 
2.13 MTT Cell Proliferation Assay 
 
Cells were plated (7.5 ×103 cells / well) in septuplicate onto a 96-well cultured plate 
and treated with 50mM lactose or 50mM sucrose for 2 or 4 days. To measure the cell 
proliferation, 20μl of 5 mg/ml MTT (Sigma) was added into each well, including 
one set of wells with MTT but no cells for control and incubated for 3.5 hours at 
37˚C in culture hood. 150μl of DMSO was then added into wells and the plate was 
put on the shaker for 5 minutes. Cell viability was expressed as optical density (OD), 
which was detected in the enzyme-linked immunosorbent assay (ELISA) reader at 
590 nm wavelength.  
 
2.14 Cell Adhesion Assay 
For BMOL cells, the final cell suspension for the adhesion assay contained 2×106 
viable cells/ml in serum-free medium. Plate was coated with 10% poly-ly-sine for 
positive control or laminin for 2 hour at 37°C then blocked with 1 % BSA for 1hour. 
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The plate was then washed with PBS. The cell suspensions were preincubated with 
50mM lactose or 50mM sucrose for 2 hour prior to plating. To initiate adhesion, 
50 μl (1×105 cells) per well was plated. Adhesion was allowed to proceed for up to 
1 hour at 37 °C/ 5% CO2. After incubation, the plate was washed twice at room 
temperature with PBS. The attached cells are then fixed with methanol for 2 min. 
The methanol was then flicked off, and the plate was incubated with Diff-Quick pink 
solution for 2 min. The solution was flicked off then the plate was incubated with 
Diff-Quick blue solution for 2 min. The plate was washed with tap water then 50μl 
DMSO was added into wells. The plate was then read in a plate reader at 660 nm 
wavelength. The average absorbance of ten wells was then obtained.  
 
2.15 ELISA Assay 
 
The quantity of galectin-3 was measured by the Duoset ELISA Development kit 
(R&D Systems) according to the manufacturer’s instruction. 100μl of capture 
antibody was diluted to the working concentration (2.0 μg/mL) in PBS and coated 
on 96-well plate overnight at room temperature. The plate wash then washed with 
wash buffer three times and blocked with 1% BSA for 1 hour. 100μl of sample 
medium and the standard reagents was then added into the plate and incubated for 2 
hours at room temperature. The plate wash washed and 100μl of the detection 
antibody, diluted in 1% BSA was added to each well and incubated for 2 hours at 
room temperature. Following washing step 100μl of the working dilution of 
Streptavidin-HRP was added to each well and incubated for 20 minutes at room 
temperature; direct light was avoided. After washing, 100μl of Substrate Solution 
was added to each well and incubated for 20 minutes at room temperature; direct 
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light was avoided. 50μl of stop solution: 2 N H2SO4 was then added the plate was 
gently shaked. The optical density was then determined by reading by the plate 
reader at 450 nm wavelength 
 
2.16 Microscopy and Image Capture 
 
For light microscopy, Axioskop microscope 40 (Carl Zeiss UK Ltd) was used with a 
Media cybernetics digital camera. Images were analyzed using Qcapture software. 
Image processing was performed using Adobe Photoshop software (Adobe Systems 
UK, Uxbridge, Middlesex, UK).  
 
2.17 Statistical analysis 
 
Paired data columns were evaluated using a two-tailed Student’s t test with GraphPad 




















The role of galectin-3 in LPC induction, proliferation, and differentiation were 
investigated in an experimental model of LPC induction, the CDE diet. Here, the role 
of galectin-3 in LPC induction and proliferation in vivo was investigated by 
analyzing the livers of CDE-fed galectin-3 null mice. In addition, the role of 
galectin-3 in LPC proliferation and differentiation in vitro were also examined by 
isolating primary LPCs from the livers of CDE-fed galectin-3 null mice. I identified 
the important role of galectin-3 in initiating LPC induction and LPC proliferation in 
vivo. Moreover, I demonstrated that galectin-3 is crucial for LPC proliferation but is 



















Liver progenitor cells (LPCs) respond to hepatic injury when hepatocyte division is 
impaired in chronic or severe injuries. Numerous studies have been done to 
characterize LPCs further due to their regenerative role in numerous liver diseases 
and their great potential as alternative treatments besides liver transplantation. LPCs 
are intimately surrounded by a complex of cells and molecules referred to as the 
“LPC niche”. This microenvironment composes of myofibroblasts, macrophages and 
the basement membrane laminin which has been suggested to play an important role 
in maintaining LPCs in an undifferentiated state within the niche (Lorenzini et al., 
2010). Here, I propose that extracellular laminin may interact with proteins expressed 
on the cell membrane of LPC and modulate LPC proliferation and differentiation.  
 
Galectin -3 is a member of the β-galactoside-binding lectin of 30 kDa family. It is 
composed of a short NH2-terminal domain, a repeated collagen-like sequence, and a 
carbohydrate recognition (CRD) domain which can binds to various glycoproteins 
such as intergrins and ECM (Liu et al., 1990; Hughes et al., 1994). Galectin-3 has 
been reported to bind integrins and regulate β1 mediated adhesion to ECM 
(Friedrichs et al., 2008; Saravanan et al., 2009). Galectin-3 is involved in various 
biological phenomena, including cell growth and proliferation (Moutsatsos et al., 
1987; Inohara et al., 1998), adhesion (Kuwabara and Liu, 1996; Inohara and Raz, 
1995; Inohara et al., 1996) and cell survival (Yang et al., 1996; Akahani et al., 1997). 
However, little research about the function of galectin-3 in the physiologic and 
pathologic processes of the liver has been published (Henderson et al., 2006; 
Shimonishi et al., 2001; Hsu et al., 1999; Santucci et al., 2000). Galectin-3 
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expression has been found significantly increased in regenerative nodules of cirrhotic 
liver tissues and in hepatocellular carcinoma (Hsu et al., 1999). Moreover, galectin-3 
has been found to modulate the growth of fibroblasts by interacting with their surface 
glycoconjugates (Inohara et al., 1998); however, the role of galectin-3 in regulating 
LPC proliferation and differentiation has never been demonstrated. 
 
Here, I examined the hypothesis that galectin-3 regulates LPC proliferation and 
differentiation in an experimental model of LPC induction, CDE diet, using mutant 
mice lacking the gene encoding galectin-3 which were generously given by Professor 
Sethi. 
 
Galectin-3 null mice have been generated by the standard gene targeting method. 
Homologous recombination removes exons II, III, and IV, including the initiating 
codon in exon II of galectin-3. The disruption of galectin-3 in the homozygous 
mutants was confirmed by Southern blot and immunostaining, showing there is no 
galectin-3 in the homozygous mutants. No overt abnormalities have been shown in 
these mutant mice with implantation and embryonic development are proceeding 













3.3.1 Galectin-3 expression is strongly associated with the LPC reaction.  
WT c57BL/6J mice were put on CDE diet for 12 days to induce chronic liver injury 
which can cause impaired hepatocyte proliferation followed by activation of LPCs. 
The expression of galectin-3 was analyzed by immunohistochemistry in the livers of 
mice that had been given CDE diet for 12 days. LPCs and macrophages were 
highlighted by the Pancytokeratin (PanCK) and the F4/80 antibody, respectively. 
Galectin-3 was found strongly expressed adjacent to the PanCK-positive LPCs when 
LPC reaction was induced by CDE diet. (Fig 3.1A, B, and D) The co-expression of 
galectin-3 and F4/80 was also observed, indicating galectin-3 was expressed by 
macrophages. (Fig 3.1B and C) Moreover, the expression of galectin-3 was 
obviously increased when LPCs were activated by CDE diet, compared to normal 
mice liver. (Fig. 3.1E) This result was also confirmed by QPCR which showed that 
CDE-fed mice had significantly higher liver galectin-3 mRNA levels than normal 
mice. (Fig. 3.1F) These data suggest that LPC activation may be regulated in a 
























Galetin-3 expression is highly associated with LPC reaction. Immunostaining for 
(A) PanCK (B) galectin-3 (C) F4/80 was performed on serial sections of liver from 
the CDE-fed mice. (D) Double staining for PanCK and galectin-3 in the livers of 
CDE-fed mice. (E) Immunostaining for galectin-3 in the livers of normal and 
CDE-fed mice. (F) Whole liver gene expression of galectin-3 from 12-day control 
and CDE diet mice. The relative mRNA levels were normalized to the housekeeping 
gene: PPIA and expressed as mean + SEM; Asterisk denotes a significant deviation 

























3.3.2 Galectin-3 is required for LPCs activation.  
To investigate the role of galectin-3 in LPC activation in vivo, both WT and 
galectin-3 null mice were put on CDE diet for 12 days and the livers from these mice 
were observed. There were few Ki67-positive hepatocytes in the livers of either 
CDE-fed WT or galectin-3 null mice (Fig 3.2A), confirming hepatocyte proliferation 
was inhibited by CDE diet. In both normal WT and galectin-3 null mouse liver, no 
LPC reactions were identified since PanCK-positive LPCs only appeared around 
biliary ducts and within or very close to the portal tracts. (Fig 3.2B) As expected, WT 
mice fed a CDE diet showed typical peri-ductular reaction of progenitor cells. (Fig 
3.2B) LPCs appeared singly or in irregular strings without lumens, and sometimes 
appeared to emerge from the biliary ducts. However, CDE-fed galectin-3 null mice 
showed only rare cells positive for panCK and these were almost exclusively bile 
ductular cells located in the periportal track. (Fig 3.2B)  
 
The numbers of PanCK-positive LPCs both in the livers of CDE-fed WT and 
galectin-3 null mice were quantified. Counts of LPCs in WT v.s. galectin-3 null mice 
confirmed a difference. (1152 ± 127.7 versus 750.9 ± 15.41 per 20x field, p=0.0076, 
n=8) (Fig 3.2C) 
 
Importantly, the absence of an LPC response in the livers of CDE-fed galectin-3 null 
mice was not associated with protection from the illness-inducing effects of the CDE 
diet on the mice. In contrast, galectin-3 null mice had higher ALT level (Fig 3.2D) 
which indicated that galectin-3 null mice had a more severe liver injury. These data 
showed that galectin-3 null mice were susceptible to CDE diet induced liver injury 










Figure 3.2 Galectin-3 null mice did not have observable LPC expansion in vivo  
(A) Immunostaining for Ki67 in the livers of CDE-fed WT and galectin-3 null mice 
(B) Immunostaining for PanCK in the livers of normal WT, galectin-3 null mice and 
CDE-fed WT and galectin-3 null mice. (C)The number of panCK- positive LPCs in 
the livers of CDE-fed WT and galectin-3 null mice (1158 versus 751 per 20x field, 
p=0.0076, n=8) (D) The level of ALT (u/l) in the livers of CDE-fed WT and 
galectin-3 null mice (246.5 versus 502, p=0.0025, n=5) Data represent mean + SEM; 
Asterisk denotes a significant deviation from the mean. (Student’s T-test, ** P<0.01) 

























3.3.3 Galectin-3 is important for LPC proliferation in vivo  
To address whether the reduced numbers of LPCs in galectin-3 null mice was 
associated with reduced proliferation of LPCs, double staining for Ki67 and PanCK 
was conducted in the livers of WT and galectin-3 null mice that had been given CDE 
diet for 12 days. (Fig 3.3A) Both the numbers of PanCK positive and Ki67/PanCK 
double positive LPCs were quantified and the percentage of Ki67 positive LPCs was 
calculated. This analysis showed a highly significant, 7-fold difference between WT 
and galectin-3 null mice (7.384% V.S. 1.2%, p=0.0072, n=5) (Fig 3.3B), confirming 





















Figure 3.3 Galectin-3 null mice had reduced LPC proliferation in response to a 
CDE diet. (A) Double immunostaining for Ki67 and PanCK in the livers of CDE-fed 
WT and galectin-3 null mice (B) The percentage of Ki67 positive LPCs in the livers 
of CDE-fed WT and galectin-3 null mice. (7.384% V.S. 1.2%, p=0.0072, n=5) Data 
represent mean + SEM; Asterisk denotes a significant deviation from the mean. 





















3.3.4 Galectin-3 plays an important role in LPC niche formation. 
To analyze the LPC niche formation in CDE-fed galectin-3 null mice, 
immunostaining for PanCK, F4/80 and laminin were performed on serial sections of 
livers from normal and CDE-fed WT/galectin-3 null mice. Similar expression 
patterns of F4/80 and laminin were observed in normal WT and galectin-3 null mice. 
(Fig 3.4A, B) Diffusely spread F4/80 positive macrophages and faint laminin 
staining were observed in both normal WT and galectin-3 null mouse liver. (Fig 3.4A, 
B) However, in the CDE-fed galectin-3 null mice macrophages remained diffusely 
spread throughout the liver whereas in the CDE- fed WT mice hepatic macrophages 
coalesced around the periportal LPC reactions. (Fig 3.4C) In addition, the expression 
of laminin was significantly increased in the livers of CDE-fed WT mice, compared 
to normal mouse liver. (Fig 3.4B, D) Moreover, laminin staining showed the 
presence of a thicker membrane that spreads from the portal tract and builds a 
network-like structure intimately surrounding the LPC reaction in the livers of 
CDE-fed WT mice. (Fig 3.4D) However, the increase in laminin expression and the 
















Figure 3.4 Absence of LPC niche formation in the livers of CDE-fed galectin-3 
null mice. Immunostaining for (A) PanCK and F4/80 (B) PanCK and laminin on 
serial sections of livers from normal WT and galectin-3 null mice. Immunostaining 
for (C) PanCK and F4/80 (D) PanCK and laminin on serial sections of livers from 































3.3.5 LPCs induction and isolation 
 
Sex- and age- matched WT c57BL/6J and galectin-3 null mice were put on CDE diet 
for 12 days to induce the activation of LPCs. Primary LPCs were isolated by Percoll 
gradient centrifugation which has been reported to separate LPCs, hepatocytes, 
erythrocytes, and debris. Generally, the 50% Percoll™ cell layer mainly consists of 
hepatocytes and the 20% Percoll™ cell layer consists of LPCs along with cells of 
similar size and density: primarily inflammatory cells and some other minor cell 
populations such as myofibroblasts and endothelial cells. (Tirnitz-Parker et al., 2007) 
Here, we isolated cells from the 20% Percoll™ cell layer. The established cultures 
were not pure but consisted mainly of LPCs. In order to get a purer population of 
LPCs, CD45 positive cells (hematopoietic cells) were depleted by using magnetic 
beads. (Fig 3.5A) Myofibroblasts usually attach to the plates later than LPCs, thus 
they can be removed by changing medium after 12 hours of culturing the isolated 
primary LPCs. In addition, the contamination of endothelial cells can be reduced by 
reducing the concentration of growth serum from 10% to 5% in the culture medium. 
Here, primary LPCs were successfully derived from the livers of CDE-fed WT and 
galectin-3 null mice. After seven days of culture either on laminin-coated or plastic 
plates, cells appeared with oval morphology and a high nuclei/cytoplasm ratio. 
Around 60% of cells (34.9 ± 5.97 cells/ per 20x field) were panCK positive LPCs 











Figure 3.5 LPCs isolation (A) Isolation of primary LPCs from the livers of 
CDE-fed mice by percoll gradients. (B) Primary LPCs derived from the livers of 
CDE-fed WT and galectin-3 null mice. Immunostaining for PanCK on primary WT 
































3.3.6 Galectin-3 is expressed and secreted by primary LPCs. 
Whether galectin-3 is secreted by primary LPCs extracellularly was assessed. 2x105 
per well of primary WT LPCs and galectin-3 null LPCs (negative control) were 
cultured in a 12 well plate for 4 days then the medium was collected. The quantity of 
galectin-3 protein level was examined by ELISA. Detection of galectin-3 protein in 
pure culture medium prior to primary LPCs culturing showed negative. Interestingly, 
there was around 48pg/ml and 33 pg/ml of galectin-3 in the medium cultured with 
primary WT LPCs on laminin-coated and plastic plates, indicating that galectin-3 
was secreted by primary WT LPCs extracellularly. (Fig 3.6A) Moreover, the 
expression of galectin-3 on primary LPCs was also analyzed by 
immunocytochemistry. Expression of galectin-3 was present in a subset of PanCK 





























Figure 3.6 Galectin-3 expression on primary WT LPCs. (A) Quantification of 
Galectin-3 protein level in pure LPC medium and LPC medium collected from 
culturing 2x105 /well WT and galectin-3 null primary LPCs for 4 days in a 12 well 
laminin-coated and plastic plate. (B) Double staining for galectin-3 and PanCK on 































3.3.7 Absence of galectin-3 inhibits proliferation of LPCs on laminin 
The role of galectin-3 in LPC proliferation in vitro was also assessed. After seven 
days of culture when LPCs exhibited oval morphology with a high nuclei/cytoplasm 
ratio, both WT and galectin-3 null primary LPCs were cultured on laminin-coated or 
plastic plates for another 4 days. These cells were then fixed and stained with PanCK 
antibody. (Fig 3.7A) Ten x20 field pictures were taken and the numbers of PanCK 
positive LPCs were quantified. After 4 days of culture, WT LPCs cultured on laminin 
increased significantly compared to galectin-3 null LPCs. (Fig 3.7B) (112.4 versus 
58.2 per 20x field, p <0.001) Interestingly, both WT and galectin-3 null LPCs which 
were cultured on plastic plates did not expand. (Fig 3.7B) This result indicates a 
































Figure 3.7 Galectin-3 null LPCs did not expand on laminin. (A) PanCK staining 
on WT and galectin-3 null LPCs which were cultured on plastic or laminin-coated 
plates at Day 0 and 4. (B) Quantification of PanCK-positive WT and galectin-3 null 
LPCs per x20 field. Data represent mean + SEM, n=3; Asterisk denotes a significant 






























3.3.8 Galectin-3 is required to maintain LPCs in an undifferentiated state. 
The role of galectin-3 in LPC differentiation in vitro was then further analyzed. To 
assess the role of galectin-3 in LPC differentiation, several different differentiation 
protocols were attempted to differentiate primary LPCs. Cultured LPCs on matrigel 
have been shown to favour biliary lineage differentiation (Li, et al., 2002). Moreover, 
it has been shown that supplementation of the medium with Epithelial growth factor 
(EGF) can generate hepatocytes (He, et al., 2003). Here, 2% matrigel and 50ng/ml 
EGF have been shown to differentiate primary LPCs into both biliary and hepatocyte 
lineages successfully. Both WT and galectin-3 null primary LPC were cultured on 
laminin and treated with 2 % matrigel and 50ng/ml EGF for 1, 3, and 5 days. (Fig 
3.8A-F) Galectin-3 null LPCs, but not WT LPCs formed a confluent monolayer 
which is similar to hepatic plate –like structure. (Fig 3.8 F, arrow) 
 
RNA was then extracted for quantitative PCR analysis. At time zero, both untreated 
WT and galectin-3 null LPCs have similar expression of the progenitor cell marker: 
DLK-1; the biliary cell markers: Aquaporin-1, CK7, and CK19; and the early 
hepatocyte marker: αFP (Fig 3.8G). After 5 days of differentiation, galectin-3 null 
LPCs had a higher expression of both the biliary cell markers: CK19, Aquaporin-1, 
GGT and the hepatocyte markers: αFP and albumin (Fig 3.8H) which indicated that 















Figure 3.8 Galectin-3 null LPCs differentiated more rapidly  
(A-F) The differentiation treatment of 2 % matrigel and 50ng/ml EGF on WT and 
galectin-3 null LPCs (on laminin-coated plates) for 3 and 5 days. (G) Quantitive PCR 
analysis of the LPC (DLK-1), the biliary cell (Aquaporin-1, CK7, and CK19), and 
the early hepatocyte (αFP) markers in undifferentiated WT and galectin-3 null LPCs. 
The relative mRNA levels were normalized to the housekeeping gene: PPIA (H) 
Quantitative PCR analysis of the biliary cell (Aquaporin-1, GGT, and CK19) and the 
hepatocyte (αFP and Albumin) markers in 2% matrigel and 50ng/ml EGF treated WT 
and galectin-3 null LPCs for 1, 3, and 5 days. The relative mRNA levels were 
compared with its basal level in untreated WT or galectin-3 null LPCs after being 
normalized to the housekeeping gene: PPIA. Data represent mean + SEM, n=3; 
Asterisk denotes a significant deviation from the mean (Student’s t-Test, 



















3.4 Discussion   
Galectin-3 is often associated with inflammation and fibrotic injury in various tissues, 
including liver. Galectin-3 expression is up-regulated in human and mouse models of 
liver fibrosis (Henderson et al., 2006) and also in hepatocellular carcinoma (Hsu et 
al., 1999). Here, I demonstrated that galectin-3 expression was significantly induced 
when LPCs were activated in the livers of CDE-fed WT mice. In addition, galectin-3 
null mice completely lacked an LPC response to the CDE model of liver injury and 
regeneration, and display showing increased liver injury over WT mice. Not only the 
total number of LPCs but also the proportion of proliferating LPCs were significantly 
reduced in galectin-3 null mice, indicating a direct effect on LPC proliferation in the 
absence of galectin-3.  
 
A previous study has shown that galectin-3 can modulate the growth of fibroblasts by 
interacting with their surface glycoconjugates (Inohara et al., 1998). In addition, 
galectin-3 can promote the proliferation of hepatic stellate cells (HSCs) (Naoto et al., 
2003). Moreover, the important role of laminin in facilitating LPC proliferation and 
maintaining LPCs in an undifferentiated state has been suggested (Lorenzini et al., 
2010). In this study, I confirmed that plating LPCs on laminin-coated plates 
facilitates their proliferation. However, galectin-3 null LPCs grew slower than WT 
LPCs when cultured on laminin-coated plates in vitro, suggesting that both laminin 
and galectin-3 are essential for LPC proliferation. Furthermore, upon treatment with 
2 % matrigel and 50ng/ml EGF for 5 days, galectin-3 null LPCs, which were 
cultured on laminin-coated plates, differentiated into biliary cells and hepatocytes 
more rapidly than WT LPCs. Taken together, these data suggested that LPCs require 
galectin-3 to expand on laminin in an undifferentiated state.  
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In this study, galectin-3 expressing cells were localized to the periportal area of the 
liver in which the regenerative proliferation of LPC is known to be initiated. In 
addition, galectin-3 expressing cells were found to co-localize with macrophages 
which are supporting cells in the LPC niche. Moreover, galectin-3 null mice failed to 
form the laminin sheaf around LPCs. Also, less recruitment of F4/80+ macrophages 
to LPCs was observed in galectin-3 null mice, compared to WT mice. This suggested 
that galectin-3 is important for LPC niche formation. Taken together, these data 
suggested that galectin-3 may be involved in cross-talk between LPCs and their 
supporting environment, which is believed to be crucial in regulating LPC 
proliferation and differentiation.  
 
Laminin has been found to form a dynamic sheath flanking proliferating LPCs and 
permits LPC proliferation in an undifferentiated form (Lorenzini et al., 2010). 
Laminin has been shown as one of the counter-receptors for galectin-3 (Ohannesian 
et al., 1995). In addition, galectin-3 modulates cell adhesion by interacting with 
integrins or extracelluar matrix such as laminin (Hughes, et al., 2001). Galectin-3 
may regulate LPC proliferation by modulating LPC adhesion to laminin. A recent 
study has shown that galectin-3 can regulate peritoneal B1-cell differentiation into 
plasma cells (Oliveira et al., 2009). It has been shown that B1 cells tend to arise early 
from fetal liver-derived precursors and become a self-renewing cell population in the 
peritoneal cavity of adult mice (Hayakawa et al. 1985; Kantor and Herzenberg 1993; 
Marcos et al. 1994). The absence of galectin-3, mesenteric membranes are a more 
adhesive substratum for mononuclear cells which favours differentiation of 
galectin-3-deficient B1 cells into plasma cells (Oliveira et al., 2009). However, here I 
hypothesize that galectin-3 enhances LPC adhesion to laminin which favours LPC 
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proliferation. The absence of galectin-3 results in a weak adhesion to laminin, thus 
favouring LPC differentiation instead of proliferation. Further research needs to be 
done to assess the role of galectin-3 in LPC adhesion to laminin which will be 

























INVESTIGATION OF THE ROLE OF EXTRACELLULAR 





The role of galectin-3 in initiating LPC activation and maintaining LPCs in a less 
differentiated state has been demonstrated in the last chapter. The exact mechanism 
by which galectin-3 regulates LPC behaviour remains unknown. The hypothesis that 
galectin-3 regulates LPC proliferation by mediating LPC adhesion to laminin was 
investigated in this chapter. In order to further understand the role of galectin-3 on 
LPC differentiation, galectin-3 siRNA was transfected into BMOLs which is an 
established LPC line derived from the livers of CDE-fed mice to knock down 
galectin-3 expression. In addition, the role of the extracellular binding activity of 
galectin-3 in LPC proliferation and adhesion to laminin is also discussed in this 















To further analyse the role of galectin-3 in the regulation of LPC proliferation and 
differentiation, it is essential to have a stable in vitro model for the study. A LPC line 
can be established from bipotential murine liver progenitor cells (BMOLs) from the 
livers of choline-deficient ethionine- supplemented (CDE)-fed mice (Tirnitz-Parker 
et al., 2007). The establishment of highly enriched LPC cultures and the derivation of 
immortalized, non-transformed, clonally derived LPC line from these culture was 
achieved by using the “plate and wait” method, that was originally developed for the 
creation of embryonic liver progenitor cell lines (Strick-Marchand et al., 2002). The 
BMOLs express both hepatic and biliary markers, and have biopotentiality to 
differentiate in to both hepatic and biliary lineages. In this study, the BMOL line was 
kindly given by Dr. Belinda Knight for the further analysis of the role of galectin-3 in 
regulating LPC proliferation and differentiation.  
 
Galectin-3 is not only found in cell cytoplasm or nucleus but also found secreted 
from cells. Galectin-3 can interact with glycosylated proteins at the cell surface or 
within the extracellular matrix. There are numerous ligands for galectin-3, including 
matrix glycoproteins: laminin, collagen IV or fibronectin and cell-adhesion 
molecules such as integrins. Galectin-3 has also been shown to regulate cell-cell and 
cell-matrix interaction. In addition, galectin-3 can modulate cell adhesion to 
extracellular matrix such as laminin by interacting with various β-galactoside 
containing glycans via its carbohydrate recognition domain (CRD) (Hughes et al., 
2001). Galectin-3 may modulate cell adhesion by inhibiting or enhancing cell-cell 
adhesion and cell interaction with extracellular matrix. In the previous chapter, I 
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concluded that galectin-3 plays an important role in the maintenance of LPCs in an 
undifferentiated state. However, how galectin-3 regulates LPC behaviour remains 
unknown. In this chapter, I hypothesise that galectin-3 regulates LPC proliferation 
and differentiation by modulating LPC adhesion to laminin. The ability of galectin-3 
in enhancing LPCs adhesion to laminin was examined. Firstly, I examined the role of 
galectin-3 in the BMOL line by transfecting galectin-3 siRNA into BMOLs to knock 
down galectin-3 expression. Lactose, a disaccharide, has been previously proved to 
compete with natural ligand recognition by galectin-3 (Platt et al., 1992; Inohara et 
al., 1994; Pienta et al., 1995). Therefore, it is widely used as a competitive inhibitor 
of galectin-3. Using a separate approach, BMOLs were treated with lactose to block 
the extracellular binding activity of galectin-3 to examine its role in LPC adhesion 























4.3.1 Galectin-3 is expressed and secreted by BMOLs. 
The expression of galectin-3 in BMOLs was examined by immunocytochemistry. 
Galectin-3 was found expressed by panCK-positive BMOLs. (Fig 4.1A) To analyze 
whether galectin-3 was secreted by BMOLs extracellularly, 2x105 per well of 
BMOLs were cultured in a 12 well plate for 4 days then the culture medium was 
collected. The quantity of galectin-3 protein level in the control culture medium and 
the medium cultured with BMOLs was examined by ELISA. Here I found that the 
control culture medium did not contain galectin-3 protein and there was around 100 
pg/ml of galectin-3 in the medium cultured with BMOLs, indicating galectin-3 was 























Figure 4.1 Galectin-3 was expressed by BMOLs. (A) Double staining for 
Galectin-3 and PanCK on BMOLs. (B) Quantification of the galectin-3 protein level 
in the control culture medium and the medium cultured with 2x105 BMOLs for 4 
days. Data represent mean + SEM; Asterisk denotes a significant deviation from the 































4.3.2. Successful knock down of galectin-3 expression in BMOLs 
To knock down galectin-3 expression in BMOLs, BMOLs were transfected with four 
different galectin-3 siRNA and scrambled siRNA as a negative control by using 
hiperfect for 1, 3, and 5 days. BMOLs were re-transfected with galectin-3 siRNA at 
day 3 to maintain the knocked down expression level of galectin-3. RNA was then 
extracted for quantitative PCR analysis. More than 75% of the galectin-3 gene 
expression was reduced by galectin-3 siRNA No.3. (Fig 4.2A) In addition, the 
protein expression level of galectin-3 in BMOLs which were transfected by 
galectin-3 siRNA No.3 for 1, 3, 5 days were also examined to confirm the reduction 



















Figure 4.2 Knock down of galectin-3 expression in BMOLs (A) Quantitative PCR 
analysis of galectin-3 in BMOLs transfected with galectin-3 siRNA No.1~ 4 for 1, 3, 
and 5 days. The relative mRNA levels were compared with its basal level in BMOLs 
which were transfected with scrambled siRNA after being normalized to the 
housekeeping gene: PPIA. (B) Lysates (10µg/lane) of BMOLs which were tranfected 
with galectin-3 siRNA NO.3 for 1, 3, and 5 days were subjected to immunoblot 




























4.3.3. Laminin is required to maintain BMOLs in an undifferentiated state. 
To confirm the role of laminin in maintaining LPCs in an undifferentiated state, 
BMOLs were cultured on laminin-coated or plastic plates and differentiated into 
hepatocyte-like cells and biliary-like cells as follows. Several differentiation 
protocols were tried to differentiate BMOLs. Oncostatin M (OSM) has been reported 
as an inducer of hepatocyte-like maturation. (Kamiya et al., 1999; Kamiya et al., 
2002; La´zaro et al., 2003) Here, BMOLs were treated with 2% matrigel, 50ng/ml 
EGF, and 30ng/ml OSM for 3 days to induce differentiation. Only BMOLs cultured 
on plastic plates but not on laminin-coated plates differentiated into duct-like 
structures after 3 days of differentiation. (Fig 4.3A, arrow) 
 
RNA was also extracted for quantitative PCR analysis. After 3 days of differentiation, 
BMOLs cultured on plastic plates had higher gene expression of both the biliary cell 
markers: CK19, Aquaporin-1, and GGT and the hepatocyte and parenchymal markers: 
HNF-4α and albumin (Fig 4.3B-F), compared to BMOLs cultured on laminin-coated 
plates. This result indicates that culturing BMOLs on laminin maintains BMOLs in a 


















Figure 4.3 BMOLs cultured on plastic plate differentiated more rapidly  
(A) The differentiation treatment of 2 % matrigel, 50ng/ml EGF, and 30ng/ml OSM 
on BMOLs cultured on plastic or laminin-coated plates for 3 days. (B~F) 
Quantitative PCR analysis of the biliary cell (Aquaporin-1, GGT, and CK19) and the 
hepatocyte (Hnf-4α and Albumin) markers in 2 % matrigel, 50ng/ml EGF, and 
30ng/ml OSM treated BMOLs cultured on plastic or laminin-coated plates for 3 days. 
The relative mRNA levels were compared with its basal level in the untreated 
BMOLs after being normalized to the housekeeping gene: PPIA. Data represent 
mean + SEM, n=3; Asterisk denotes a significant deviation from the mean. (Student’s 

















4.3.4 Galectin-3 is required for the maintenance of BMOLs in an 
undifferentiated form on laminin. 
To further analyse the effect of knocking down galectin-3 expression on BMOL 
differentiation, BMOLs cultured on laminin-coated plates were transfected with 
galectin-3 siRNA and scrambled siRNA as a negative control for two days then 
BMOLs were treated with 2 % matrigel, 50ng/ml EGF, and 30ng/ml OSM for 3 days 
to induce BMOL differentiation. (Fig 4.4A)  
 
RNA was then extracted for quantitative PCR analysis. The expression of galectin-3 
was analysed to ensure the knock down efficiency. More than 50 % of the galectin-3 
expression was reduced by galectin-3 siRNA in undifferentiated BMOLs and 
BMOLs supplemented with 2% matrigel, 50ng/ml EGF, and 30ng/ml OSM. (Fig 
4.4B) After 3 days of differentiation, BMOLs transfected with Galectcin-3 siRNA 
had higher gene expression of both the biliary cell markers: CK19, Aquaporin-1, 
GGT and the hepatocyte markers: Hnf-4α and albumin (Fig 4.4B-F), compared to 
BMOLs transefected with scrambled siRNA as a negative control. This result 
indicates that knock down of galectin-3 expression in BMOLs induces a more rapid 
differentiation into mature biliary cells and hepatocytes on laminin, suggesting 













Figure 4.4 Knock down of galectin-3 expression in BMOLs results in a more 
rapid differentiation 
(A) The differentiation treatment of 2 % matrigel, 50ng/ml EGF, and 30ng/ml OSM 
on BMOLs which were transfected with scrambled and galectin-3 siRNA for 3 days 
on laminin-coated plates. (B) Quantitative PCR analysis of galectin-3 in 
undifferentiated and 2 % matrigel, 50ng/ml EGF, and 30ng/ml OSM treated BMOLs 
which were transfected with scrambled or galectin-3 siRNA on laminin-coated plates 
for 3 days. The relative mRNA levels were compared with its basal level in BMOLs 
which were transfected with scrambled siRNA after being normalized to the 
housekeeping gene: PPIA. (C~E) The biliary cell (Aquaporin-1, GGT, and CK19) 
and the hepatocyte (Hnf-4α and Albumin) markers in undifferentiated and 2 % 
matrigel, 50ng/ml EGF, and 30ng/ml OSM treated BMOLs which were transfected 
with scrambled or galectin-3 siRNA on laminin-coated plates for 3 days. The relative 
mRNA levels were compared with its basal level in undifferentiated BMOLs after 
being normalized to the housekeeping gene: PPIA. Data represent mean + SEM, n=3; 











4.3.5 Inhibition of galectin-3 inhibits adhesion of BMOLs on laminin. 
The role of the extracellular binding activity of galectin-3 in BMOL adhesion was 
then analysed. 96 well culture plates were coated with laminin and polylysine which 
serves as a positive control for complete adhesion. 1 ×105 cells /well of untreated 
BMOLs and BMOLs which were preincubated with 50mM lactose or 50mM sucrose 
for 2 hour were plated on polylysine-coated, laminin-coated, and plastic plates. After 
1 hour, non-adherent cells were washed off and the adherent cells were stained by 
Diff-Quick stain which was designed to incorporate cytoplasmic (pink) staining with 
nuclear (blue) staining. The adherent cell number was then measured by absorbance 
at 660 nm after adding DMSO. Significantly, fewer BMOLs were adherent to plastic 
plates compared to laminin-coated plates. (Fig 4.5A) In addition, BMOLs adopted a 
flattened adherent morphology when plated on laminin-coated plates, but remained 
round and non well-adherent morphology when plated on plastic plates. (Fig 4.5B, C) 
Furthermore, preincubation of cells with lactose, a competitive inhibitor of the 
extracellular binding activity of galectin-3, significantly reduced the number of 
adherent BMOLs, compared to untreated and sucrose-treated BMOLs on laminin- 



















Figure 4.5 Reduction of the adherent cell numbers on laminin by treating 
BMOLs with lactose. (A) Adhesion of untreated and 50 mM lactose or 50 mM 
sucrose treated BMOLs to laminin - coated, and plastic plates. Polylysine coatings 
served as a positive control. Data represent mean + SEM, n=3; Asterisk denotes a 
significant deviation from the mean. (Student’s t-Test, ***P<0.001) Morphology of 
BMOLs cultured on (B) laminin-coated or (C) plastic plates for 1 hour. Original 




















4.3.6 Both laminin and the extracellular binding actvity of galectin-3 is  
important for BMOL proliferation 
To assess the role of laminin in BMOL proliferation, the MTT assay was used to 
assess BMOL proliferation. BMOLs were cultured on laminin-coated or plastic 
plates and the cell number was determined by a colorimetric MTT assay, as measured 
by absorbance at different time points: Day 0, 2 , and 4. The result indicated that 
MTT optical density (OD) value in the BMOLs cultured on laminin-coated plates is 
significantly higher than those cultured on plastic plates at day 4, suggesting the 
BMOLs cultured on laminin-coated plates grew faster than the BMOLs cultured on 
plastic plates (Fig. 4.6A) This result confirms the important role of laminin in BMOL 
proliferation.  
 
I further analysed whether the extracellular binding activity of Galetin-3 is essential 
for BMOL proliferation on laminin-coated plates. Lactose has been shown as a 
competitive inhibitor of galectin-3. BMOLs which were cultured on laminin-coated 
plates were treated with 50mM of lactose to block the extracellular binding activity 
of galectin-3 or 50 mM of sucrose as a negative control. BMOL proliferation was 
then assessed by the MTT assay. The result showed that MTT optical density (OD) 
value in lactose treated BMOLs is significantly lower than the untreated BMOLs and 
those treated with sucrose, indicating BMOLs treated with lactose grew slower than 









Figure 4.6 Laminin and the extracellular binding activity of galectin-3 are both 
important for BMOL proliferation. (A) MTT assay in BMOLs cultured on 
laminin- coated and plastic plates at Day 0, 2, and 4 (B) MTT assay in BMOLs 
cultured on laminin- coated plates with or without treatment of 50mM lactose, 50mM 
sucrose (negative control) at Day 0, 2, and 4. Cells were seeded at a density of 7.5 
×103 cells/well supplemented with growth medium containing 10% FCS. Data 
represent mean + SEM, n=3; Asterisk denotes a significant deviation from the mean 




















BMOLs were used in this chapter to further analyse the mechanisms of galectin-3 
modulating LPC proliferation and differentiation since LPC line is easier to work on 
for studies such as knock down of galectin-3 expression by trasfecting galectin-3 
siRNA or cell adhesion and proliferation assay. In fact, primary LPCs are resisted to 
transfection with siRNA. I firstly showed that galectin-3 was expressed by BMOLs 
and secreted by BMOLs extracellularly into medium. In addition, previous studies 
have indicated that BMOLs express both the hepatic and biliary markers, indicating 
their biopotentiality to differentiate into both hepatic and biliary lineages 
(Strick-Marchand et al., 2002). Upon the treatment of 2% matrigel, 50ng/ml EGF, 
and 30ng/ml OSM for 3 days, the biliary cell marker: CK19, aquaporin-1, and GGT 
and the hepatocyte marker: albumin and HNF4α were significantly up-regulated in 
BMOLs to confirm the ability of BMOLs to differentiate into both hepatic and 
biliary lineages. 
 
The role of laminin in BMOL differentiation was then assessed. BMOLs 
differentiated into hepatic and biliary lineages more rapidly when cultured on plastic 
plates compared to laminin-coated plate. In addition, knock down of galectin-3 
expression in BMOLs led to differentiation into both hepatic and biliary lineages 
more rapidly even if cultured on laminin-coated plates. This result is similar to my 
study of galectin-3 null primary LPC differentiation in the previous chapter, further 
confirming that the absence or the knock down of galectin-3 expression lead to a 
more rapid LPC differentiation. Moreover, I also indicated that BMOLs cultured on 
laminin grew faster than those cultured on plastic-coated plates which confirmed the 
essential role of laminin in promoting LPC proliferation. Taken together, I confirmed 
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that both laminin and galectin-3 are required for the maintenance of LPCs in an 
undifferentiated state to promote LPC proliferation. However, the exact mechanism 
of galectin-3 regulating LPC proliferation and differentiation remains unknown. 
Previous studies indicated that galectin-3 promotes neural cell adhesion on laminin 
and neurite growth (Penka et al., 1998). Here, I propose that galectin-3 enhance LPC 
adhesion to laminin to maintain LPCs in an undifferentiated state and promote LPC 
proliferation.  
 
Whether galectin-3 plays an important role in BMOL adhesion to laminin was then 
investigated. Previous studies have shown that galectin-3 modulate cell adhesion to 
extracellular matrix such as laminin by interacting with various β-galactoside 
containing glycans via its carbohydrate recognition domain (CRD) (Hughes et al., 
2001). Galectin-3-mediated effects on cell adhesion may be either positive enhancing 
or negative inhibitory (Hughes et al., 2001). For example, breast cancer cell with 
high expression of galectin-3 interact well and spread very rapidly on ECM proteins 
compared to those with low or no galectin-3 expression (Warfield et al., 1997; 
Matarrese et al., 2000; Honjo et al., 2001). Galectin-3 significantly increased the 
adhesion of human neutophils to various substrata (Lotan et al., 1994; Kuwabara et 
al., 1996). However, galectin-3 has been shown to reduce the adhesion of myoblasts 
and kidney epithelial cells to laminin (Sato et al., 1992). 
 
Here, I have found that laminin profoundly promoted BMOL adhesion. In addition, 
treating BMOLs with lactose significantly reduced BMOL adhesion to laminin, 
suggesting that the extracellular binding activity of galectin-3 has a positive effect on 
BMOL adhesion to laminin. Moreover, the role of the extracellular binding activity 
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of Galetin-3 in BMOL proliferation was also assessed. Compared to the untreated 
and sucrose- treated BMOLs, the lactose-treated BMOLs grew slower after 4 days of 
culture, suggesting the extracellular binding activity of Galetin-3 is essential for 
BMOL proliferation. Taken together, these data suggest the extracellular binding 
activity of galectin-3 is important for LPC adhesion to laminin and LPC 
proliferation. 
 
However, it is still not clear how galectin-3 regulates BMOL adhesion to laminin. 
Galectin-3 can modulate cell adhesion by binding to the molecules involved in cell 
adhesion directly or by steric hindrance of the interaction between molecules 
involved in cell-cell or cell-matrix adhesion. The mechanism may also involve 
integrin activation (Hughes et al., 2001, detail mechanism is shown in the chapter 
one). Whether galectin-3 modulation of  BMOL adhesion to laminin involves 
integrin activation remains unknown. Further research needs to be conducted to 
answer this question.  
 
In summary, I confirmed the regulating role of galectin-3 in LPC proliferation and 
differentiation based on the finding in this chapter and the previous chapter, either by 
investigating galectin-3 null primary LPCs or knocking down galectin-3 expression 
in BMOLs. Galectin-3 is important for LPC proliferation, but the absence of 
galectin-3 leads LPCs to differentiate into both lineages more rapidly on laminin. 
These data not only confirm that galectin-3 is required to maintain LPCs in an 
undifferentiated state but also suggest that galectin-3 is crucial in mediating the 
homeostatic balance between proliferation and differentiation of LPCs. In addition, I 
also showed that competitive inhibition of galectin-3 inhibited adhesion and 
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proliferation of LPCs on laminin, suggesting that galectin-3 is required for LPCs to 

























CHAPTER 5  
 
INVESTIGATION THE ROLE OF GALETIN-3 IN REGULATING 
CELL CYCLE AND CELL-ADHESION SIGNALLING PATHWAY  
 
5.1 Abstract 
The importance of galectin-3 in maintaining LPC in an undifferentiated state on 
laminin has been demonstrated in the first and second chapter. Additionally, the 
second chapter demonstrated the role played by the extracellular binding activity of 
galectin-3 in promoting LPC proliferation and enhancing LPC adhesion to laminin. 
However, the mechanism of galectin-3 regulating LPC proliferation was not 
completely investigated. Galectin-3 may regulate LPC proliferation by regulating the 
activity of cell cycle regulators or cell-adhesion mediated signalling pathways. In 
addition, galectin-3 may also indirectly mediate β1 integrin activation by binding to 
and activating the heterodimeric transmembrane amino acid transporter CD98. This 
chapter demonstrates that the absence of galectin-3 or the knock down of galectin-3 
expression leads to down-regulation of cyclin D1 and up-regulation of p16 and p21. 
In addition, down-regulation of FAK and Akt phosphorylation was observed in 
galectin-3 null LPCs and galectin-3 siRNA transfected BMOLs. Moreover, CD98 
and integrin β1 expression are strongly associated with activation of LPCs. Also, 
CD98 and integrin β1 are expressed by panCK and galectin-3 positive cells in vitro, 
especially on dividing cells. These results suggest that integrin β1 and CD98 may be 





Galectin-3 is expressed ubiquitously in the cytoplasm, the nucleus, extracellular 
compartment, and at the cell surface. Thus, galectin-3 medicates multiple functions 
depending on its subcellular localization. Generally, extracellular galectin-3 
modulates cell adhesion and cell - cell interactions via its CRD domain, while 
intracellular galectin-3 mediates several signal transduction pathway (Ochieng et al., 
2004; Nakahara et al., 2005; Susumu et al., 2007). Nuclear galectin-3 has been found 
as a nuclear matrix protein and involved in pre-mRNA splicing (Park et al., 2001; 
Wang et al., 2004; Paces-Fessy et al., 2004; Susumu et al., 2007). The mechanism in 
which galectin-3 regulates LPC proliferation is not completely known. However, the 
previous chapter demonstrated that the extracellular binding activity of galectin-3 is 
important for LPC proliferation and LPC adhesion to laminin. Galectin-3 may 
regulate LPC proliferation by mediating LPC adhesion to laminin. It is also possible 
that extracellular galectin-3 cross-links surface glygoproteins such as signaling 
molecules kinases and transduces signals to regulate LPC proliferation. Furthermore, 
the nuclear galectin-3 may also regulate LPC proliferation intracellularly. Galectin-3 
has been shown to shuttle between the nucleus and cytoplasm and is engaged in 
pre-mRNA splicing and the regulation of cancer-related gene expression (Susumu et 
al., 2007; Lin et al., 2002; Paron et al., 2003; Song et al., 2003) or cell growth, 
apoptosis, and cell-cycle progression (Dagher et al., 1995; Wang et al., 2004). 
Galectin-3 might modulate transcription factors to regulate cyclin D or c-myc gene 
expression which are involved in cell proliferation.  
 
Galectin-3 has been reported to bind integrins and regulates β1 mediated adhesion to 
ECM (Friedrichs et al, 2008; Saravanan et al., 2009). In addition, galectin-3 may also 
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indirectly mediate integrin β1 activation by binding to the heterodimeric 
transmembrane amino acid transporter CD98 (Dong et al, 1997; MacKinnon et al., 
2008). CD98, a ligand for galectin-3 and an endogenous target for galectin-3 in 
activaton of integrins, may be involved in the regulation of LPC proliferation. 
Galectin-3 may mediate the binding activity of CD98 with integrin β1 and activate 






























5.3.1. Galectin-3 regulates the expression of cyclin D1, p16 and p21 
In order to further investigate the role of galectin-3 in LPC proliferation, the 
expression of cell cycle regulators were examined. Both WT and galectin-3 null 
LPCs were isolated from the livers of the CDE-fed WT and galectin-3 null mice. 
After seven days of culture when primary LPCs adopted oval morphology with a 
high nuclei/cytoplasm ratio, both WT and galectin-3 null primary LPCs were 
cultured on laminin-coated or plastic plates for another 4 days. Total cell lysates were 
then collected from WT and galectin-3 null LPCs. Immunoblot analysis showed that 
cyclin D1 protein expression was down-regulated in galectin-3 null LPCs either 
cultured on laminin-coated or plastic plates. (Fig 5.1A, B) In addition, the gene 
expression of cell cycle inhibitors p21 and p16 were also examined. RNA from WT 
and galectin-3 null primary LPCs which were cultured with serum free medium for 1 
day (time zero) or medium contains 5% serum for 4 days, respetively, was extracted 
for quantitative PCR analysis. The expression of p21 and p16 were both up-regulated 
in galectin-3 null LPCs which were either cultured on laminin-coated or plastic 


































Figure 5.1 Galectin-3 down-regulated cyclin D1 but up-regulated p16 and p21.  
(A) Lysates (10µg/lane) of WT and galectin-3 null primary LPCs which were 
cultured on laminin-coated plates (L) or plastic plates (P) for 4 days were subjected 
to immunoblot analysis with an anti-cyclin D1, and anti-β-actin antibodies. (B) 
Respective densitometry. Quantitative PCR analysis of P16 in WT and galectin-3 
null LPCs which were cultured on (C) laminin-coated plates or (D) plastic plates for 
4 days. Quantitative PCR analysis of P21 in WT and galectin-3 null LPCs which 
were cultured on (E) laminin-coated or (F) plastic plates for 4 days. The relative 
mRNA levels were compared with WT and galectin-3 null LPCs which were cultured 
in serum-free cultured medium after being normalized to the housekeeping gene: 
PPIA. Data represent mean + SEM, n=3; Asterisk denotes a significant deviation 















5.3.2 A decrease in phosphorylation of FAK, Akt was observed in galectin-3 null 
LPCs when cultured on plastic plates. 
Cell adhesion-mediated cyclin D1 promoter activation appears to occur through focal 
adhesion kinase (Zhao et al., 1998). The tyrosine phosphorylation of the 
integrin-linked FAK and its downstream kinases Akt has been shown to play an 
important role in adhesion-mediated signal transduction (Schwartz et al., 2002). This 
study addressed the question as to which cell adhesion-mediated signalling 
pathwaywas regulated by galectin-3.  
 
As shown in figure 5.2, the phosphorylation of FAK was reduced in galectin-3 null 
LPCs when cultured on plastic plates, but only a slight reduction can be observed in 
galectin-3 null LPC when cultured on laminin-coated plates (Fig 5.2 A, B). Similarly, 
an obvious decrease in Akt phosphorylation was observed in the galectin-3 null LPCs 
when cultured on plastic plates but there was only a slight reduction of Akt 
phosphorylation in the galectin-3 null LPCs when cultured on laminin-coated plates. 




















Figure 5.2 Western blots showing levels of the expression of phosphorylation of 
FAK and Akt in WT and galectin-3 null LPCs when cultured on laminin-coated 
or plastic plates (A) Lysates (10µg/lane) of WT and galectin-3 null primary LPCs 
which were cultured on laminin-coated or plastic plates for 4 days were subjected to 
immunoblot analysis with an anti-phospho FAK, anti-phospho Akt, and anti- β-actin 





















5.3.3 No difference in activation of β-catenin and G3K3β was observed in 
galectin-3 null LPCs 
It has been shown that galectin-3 plays a role in Wnt signaling in breast cancer by 
interacting with β-catenin. Galectin-3 binds to β-catenin and colocalize it in the 
nucleus to stimulate the expression of cyclin D1 (Shimura et al., 2004). Thus the role 
of galectin-3 in β-catenin and GSK3β activation during LPC proliferation was 
investigated. In order to achieve this, the expression of active β-catenin and 
phosphorylation of GSK3β was assessed. Immunoblot analysis of total cell lysates 
showed that both the expression of active β-catenin and phosphorylation of GSK3 
were comparable between WT and galectin-3 null primary LPCs cultured either on 























Figure 5.3 Western blots showing no difference in the expression of active 
β-catenin and phosphorylation of GSK3 in WT and galectin-3 null LPCs when 
cultured on laminin-coated or plastic plates (A) Lysates (10µg/lane) of WT and 
galectin-3 null primary LPCs which were cultured on laminin-coated or plastic plates 
for 4 days were subjected to immunoblot analysis with an anti- active β-catenin, anti- 





















5.3.4 Knock down of galectin-3 expression down-regulated cyclin D1 and 
up-regulated p16 and p21.  
In order to further confirm the role of galectin-3 in regulating the expression of 
cyclin D1, p16, and p21, galectin-3 expression was knocked down in LPC line: 
BMOLs by transfecting galectin-3 siRNA into BMOLs. BMOLs which were cultured 
on laminin-coated or plastic plates were transfected with scrambled siRNA or 
galectin-3 siRNA. Total RNA and cell lysates were collected after 1, 3, and 5 days of 
transfection.  
 
To confirm the galectin-3 knocked down efficiency, galectin-3 protein expression 
was analyzed in BMOLs after transfection. (Fig 5.4A-B, D-E) The efficiency of 
knocking down galectin-3 expression was further confirmed by quantitative PCR 
analysis, demonstrating that the mRNA level of galectin-3 was significantly reduced 
after transfection. (Fig 5.4 G, H) The cyclin D1 protein expression was then further 
analyzed in BMOLs after transfection. Cyclin D1 expression was reduced in BMOLs, 
either cultured on laminin-coated or plastic plates after knocking down galectin-3 
expression for 5 days. (Fig 5.4A, C, D, F)  
 
The mRNA levels of p16 and p21 in the transfectants were also analyzed. P16 
expression was significantly up-regulated in BMOLs which were transfected with 
galectin-3 siRNA and cultured either on laminin-coated (Fig 5.4 I) or plastic plates 
(Fig 5.4 J) after 3 and 5 days of transfection. P21 expression was also significantly 
up-regulated after 3 days of transfection. (Fig 5.4 L, K) Interestingly, the mRNA 
level of p21 was reduced in both BMOLs transfected with scrambled siRNA or 
galectin-3 siRNA after 5 days of transfection either on laminin-coated plates (Fig 5.4 
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L) or plastic plates (Fig 5.4 K) However, the mRNA level of p21 in BMOLs 
transfected with galectin-3 siRNA was still significantly higher than BMOLs 
































Figure 5.4 Knock down of galectin-3 expression in BMOLs down-regulated 
cyclin D1 but up-regulated p16 and p21.  
Lysates (10µg/lane) of BMOLs which were cultured on (A) plastic or (D) 
laminin-coated plates and trasfected with scrambled or galectin-3 siRNA for 1, 3, 
and 5 days were subjected to immunoblot analysis with an anti- galectin-3, 
anti-cyclin D1, and anti- β-actin antibodies. (B-C, E-F) Respective densitometry 
Quantitative PCR analysis of galectin-3 in BMOLs which were cultured on (G) 
laminin-coated or (H) plastic plates after 1, 3, and 5 days of transfection. 
Quantitative PCR analysis of p16 in BMOLs which were cultured on (I) 
laminin-coated or (J) plastic plates after 1, 3, and 5 days of transfection. Quantitative 
PCR analysis of p21 in BMOLs which were cultured on (L) laminin-coated or (K) 
plastic plates after 1, 3, and 5 days of transfection. The relative mRNA levels were 
compared with transfectants which were transfected with scrambled siRNA or 
galectin-3 siRNA for 1 day after being normalized to the housekeeping gene: PPIA. 
Data represent mean + SEM, n=3; Asterisk denotes a significant deviation from the 











5.3.5 A decrease in FAK and Akt phosphorylation was observed in galectin-3 
siRNA-transfected BMOLs which were cultured on plastic plates.  
The phosphorylation of FAK and Akt was also investigated after transfecting 
galectin-3 siRNA into BMOLs which were cultured on laminin-coated or plastic 
plates for 1, 3, and 5 days. Phosphorylation of Akt was significantly reduced in 
BMOLs cultured on plastic plates after 3 and 5 days of transfection. (Fig 5.5A, B), 
while was only reduced slightly in BMOLs cultured on laminin-coated plates after 
transfection. (Fig 5.5 D, E)  
 
Interestingly, FAK phosphorylation was increased in BMOLs which were transfected 
with scrambled siRNA, but reduced in BMOLs which were transfected with 
galectin-3 siRNA when cultured on plastic plates. (Fig 5.5A, C) However, there is 
only a slight reduction in phosphorylation of FAK after knocking down galectin-3 


















Figure 5.5 A decrease in phosphorylation of FAK and Akt was observed in 
galectin-3 siRNA transfected BMOLs cultured on plastic plates 
Lysates (10µg/lane) of BMOLs which were cultured on (A) plastic or (D) 
laminin-coated plates and trasfected with scrambled siRNA or galectin-3 siRNA for 
1, 3, and 5 days were subjected to immunoblot analysis with an anti-phospho FAK, 





















5.3.6 CD98 and integrin β1may be involved in the regulation of LPC behavior. 
It has been proposed that galectin-3 is a ligand for the glycosylated extracellular 
domain of CD98hc and is a natural activator of CD98 (Dalton et al., 2007). Thus, 
galectin-3 may synergize with CD98 in the activation of integrins. The expression of 
CD98 in the liver of CDE-fed mice was examined by immunochemistry. CD98 was 
expressed around the panCK- positive LPCs. (Fig 5.6 A, B) Double immunostaining 
for PanCK and CD98 further confirmed that CD98 was expressed around panCK- 
positive LPCs. (Fig 5.6 C) In order to identify the cell type that express CD98, the 
immunostaining for Desmin and Von Willebrand Factor (VWF) was conducted to 
identify the hepatic stellate cells and endothelial cells, respectively, on serial sections 
of livers from CDE-fed WT mice. CD98 was expressed around the hepatic stellate 
cells (Fig 5.6 D, E and 5.6 G, F); however, it’s not very clear whether CD98 was 
expressed around the VWF-positive endothelial cells. (Fig 5.6 E, F, C and 5.6 G, I)  
 
Moreover, the expression of CD98 was increased and especially localized around the 
LPC reaction in the liver of CDE-fed WT mice, compared to the liver of normal WT 
mice. (Fig 5.7A) However, the expression pattern of CD98 in the liver of CDE-fed 
galectin-3 mice is similar to the liver of normal galectin-3 null mice. No obvious 
increase in the expression of CD98 in the liver of CDE-fed galectin-3 null mice can 
be observed. (Fig 5.7A) 
 
Furthermore, the expression of integrin β1 in the liver of CDE-fed WT mice was 
investigated. It was observed that integrin β1 was highly expressed on hepatocytes 
but not on bile ducts in the liver of normal WT mice, whereas its expression was 
specifically restricted to the bile ducts in the liver of CDE-fed WT mice. (Fig 5.7B) 
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However, integrin β1 was widely expressed on hepatocytes in the liver of both 



































Figure 5.6 CD98 was expressed around LPCs and hepatic stellate cells. 
Immunostaining for (A) PanCK (B) CD98 on serial sections of livers from CDE-fed 
WT mice (C) Double immunostaining for PanCK and CD98 in the liver of CDE-fed 
WT mice. Immunostaining for (D, G) Desmin (E, H) CD98 (F, Q) VWF on serial 



























Figure 5.7 Different expression pattern of CD98 and integrin β1 in the livers of 
the CDE-fed WT and galectin-3 null mice. Immunostaining for (A) CD98 (B) 
integrin β1 in the livers of normal WT, galectin-3 null mice and CDE-fed WT and 























5.3.7 Both CD98 and integrin β1 were expressed by PanCK or galectin-3 
positive cells, especially on the dividing cells.   
The expression of CD98, galectin-3 and integrin β1 on primary LPCs was then 
investigated. Anti-CD29 antibody was used to highlight integrin β1. CD98 was 
frequently expressed by panCK- positive LPCs. In particular, it was highly expressed 
on dividing panCK-positive LPCs (Fig. 5.8A, arrows). The co-expression of CD98 
and galectin-3; galectin-3 and integrin β1; and CD98 and integrin β1 were all 
observed on primary LPC culture. (Fig 5.8A) Interestingly, CD98, galectin-3 and 
integrin β1 were expressed highly around the dividing cells. (Fig 5.8A, arrows)  
  
A similar expression pattern of CD98, galectin-3 and integrin β1 was also observed 
in LPC line: BMOLs. CD98 and integrin β1 were both expressed by panCK- positive 
BMOLs. (Fig 5.8B) Similarly, the co-expression of CD98 and galectin-3 was also 





























Figure 5.8 Expression of CD98,galectin-3, and integrin β1 on primary LPCs and 
LPC line: BMOLs (A)Double staining for panCK and CD98, CD98 and galectin-3, 
galectin-3 and integrin β1 CD98 and integrin β1 on primary LPCs. (B) Double 
staining for integrin β1 and panCK, CD98 and galectin-3, CD98 and panCK on LPC 























Previous studies have shown that galectin-3 plays a role in regulating cell cycle. 
Apart from activating cyclin D1 promoter (Lin et al., 2002), galectin-3 has also been 
demonstrated to regulate the expression of cell cycle inhibitors. Galectin-3 
knockdown in human prostate cancer cells led to cell-cycle arrest at G1 phase, 
up-regulation of p21, and hypophosphorylation of the retinoblasma tumor supressor 
protein (pRb) (Wang. et al., 2009). This chapter demonstrated that cyclin D1 protein 
expression in galectin-3 null primary LPCs was significantly reduced compared to 
WT primary LPCs. In addition, the knock down of galectin-3 in the LPC line: 
BMOLs also significantly down-regulated cyclin D1 expression, confirming the role 
of galectin-3 in regulating cyclin D1 expression. Moreover, the expression of cell 
cycle inhibitors p16 and p21 was significantly up-regulated in galectin-3 null primary 
cells. This up-regulation of p16 and p21 was also observed in galectin-3 
siRNA-transfected BMOLs. Surprisingly, after 5 days of transfection, the expression 
of p21 was reduced in the BMOL cells, regardless of whether they were transfected 
with scrambled or galectin-3 siRNA. This observation may be attributed to the fact 
that the cells were cultured for long period of time. However, the expression of p21 
in the BMOL cells transfected with galectin-3 siRNA was still higher than that in the 
BMOLs transfected with scrambled siRNA. These findings suggest a role for 
galectin-3 in regulating the expression of cell cycle regulators. The absence or the 
knocking down of galectin-3 expression down-regulates cyclin D1 and up-regulates 
p16 and p21. 
 
Galectin-3 has been shown to bind to β-catenin which is involved in the regulation of 
the Wnt signalling pathway, thus stimulates the gene expression of cyclin D1 
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(Shimura et al., 2004). Previous studies indicated that the down-regulation of 
galectin-3 reduces the level of β-catenin and cyclin D1 in human colon cancer cells 
(Song et al., 2009). Down-regulation of galectin-3 also resulted in the 
dephosphorylation of glycogen synthase kinase-3β (GSK-3β), which is involved in 
Wnt pathway (Song et al., 2009). However, this differential expression of β-catenin 
and GSK-3β reported by Song and co-workers was not observed in WT and 
galectin-3 null LPCs. Further research needs to be carried to investigate whether the 
Wnt pathway is involved in the mechanisms of galectin-3 regulating LPC 
proliferation.  
  
How galectin-3 regulates cyclin D1 remains unknown. It has been shown that cell 
adhesion- mediated cyclin D1 promoter activation appears to occur through focal 
adhesion kinase (Zhao et al., 1998). However, it was also demonstrated that 
galectin-3 induces cyclin D1 promoter activity in human breast epithelial cells 
independent of cell adhesion. Lin et al (2002) proposed that galectin-3 might be 
involved in the enhancement/stabilization of nuclear protein-DNA complex 
formation at the CRE site of the cyclin D1 promoter (Lin et al., 2002). In this study it 
was observed that the phosphorylation of FAK and Akt were reduced when 
galectin-3 null LPCs were cultured on plastic plates. However, only a slight 
reduction of FAK phosphorylation was observed when galectin-3 null LPCs were 
cultured on laminin-coated plates. Unexpectedly, no difference in Akt 
phosphorylation was observed between WT and galectin-3 null LPCs when cultured 
on laminin-coated plates. This similar expression pattern was also observed when the 
expression of galectin-3 was reduced in BMOLs. Phosphorylation of FAK and Akt 
was reduced in the galectin-3 siRNA- transfected BMOLs cultured on plastic but not 
 183
on laminin-coated plates. This result suggests that other mediators may compensate 
for the loss of galectin-3 to mediate the phosphorylation of FAK and Akt when LPCs 
were cultured on laminin-coated plates. However, the phosphorylation of FAK and 
Akt normally occurs within 5 minutes to 1 hour. Therefore, the time points used in 
this study may not be suitable for the investigation of FAK and Akt phosphorylation. 
Further research need to be conducted to make any firm conclusion about this. 
Exogenous galectin-3 can be added into galectin-3 null primary LPCs at various time 
points from 5 minutes to 1 hour to further investigate whether galectin-3 mediate 
FAK and Akt phosphorylation when culturing LPCs on laminin-coated plates. 
Nevertheless, this study still demonstrated the role of galectin-3 in mediating the 
phosphorylation of FAK and Akt in LPCs when cultured on plastic plates.   
 
Further research still needs to be conducted to investigate whether mediating 
cell-adhesion signalling pathways are involved in the mechanism by which 
galectin-3 regulates the expression of cell cycle regulators and LPC proliferation. It 
has been shown that basement membrane of bile ducts comprises laminin and type 
IV collagen (Terada et al., 1994; Yasoshima et al., 2000). However, whether integrin 
activation is involved in the regulation of LPC proliferation is not clear. It has been 
shown that both CD98 and galectin-3 interact with integrin β1 and can mediate 
certain integrin β1 functions (Fenczik et al., 1997; Merlin et al., 2001; Henderson et 
al., 2006; Feral et al., 2005; Hughes, et al., 2001). It is thus possible that galectin-3 
regulates the binding activity of CD98 with integrin β1 which may mediate the 
adhesion of LPC to laminin and regulate LPC proliferation and differentiation. In this 
study, the preliminary data has shown that both CD98 and integrin β1 were expressed 
on panCK-positive LPCs in vitro. The co-expression of galectin-3 and CD98, 
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galectin-3 and integrin β1; CD98 and integrin β1 was observed in LPC culture. 
Interestingly, they were all expressed on dividing cells, suggesting that galectin-3, in 
conjuction with CD98 and integrin β1, may play an important role in the regulation 
of LPC proliferation.  
 
Moreover, the expression of CD98 and integrin β1 is related to LPC activation. 
CD98 was expressed around panCK-positive LPCs. Also, CD98 expression was 
increased and especially localized around the area of LPC activation when LPCs 
were activated in the liver of CDE-fed WT mice, proposing that CD98 plays a role in 
regulating LPC activation. However, an increase in CD98 expression was not 
observed in the liver of CDE-fed galectin-3 null mice. This suggested that galectin-3 
may regulate CD98 expression when LPCs were activated. Furthermore, integrin β1 
was widely expressed on hepatocyte in the liver of normal WT mice. On the other 
hand, the expression of integrin β1 was restricted to the bile ductules in the liver of 
CDE-fed WT mice, suggesting that integrin β1 expression is associated with LPC 
activation. However, this expression pattern was not observed in galectin-3 null mice. 
Integrin β1 was widely expressed on hepatocyte both in the liver of normal and 
CDE-fed galectin-3 null mice. These results suggested a role for galectin-3 in 
modulating integrin β1 expression during LPC activation. Taken together, these data 
demonstrated that the expression of CD98 and integrin β1 were associated with LPC 
activation and may be regulated by galectin-3. However, further research needs to be 
conducted to assess whether galectin-3 and CD98 are both involved in integrin 
activation and the regulation of LPC proliferation.  
 
In summary, this study indicated that the absence of or the knock down of galectin-3 
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expression down-regulated cyclin D1 but up-regulated p21 and p16 in LPCs. In 
addition, it seems that Wnt/β-catenin signalling pathway is not regulated by 
galectin-3 during LPC proliferation. Although the down-regulation of FAK and Akt 
phosphorylation was observed when galectin-3 null LPCs or galectin-3 
siRNA-transfected BMOLs were cultured on plastic plates, more research needs to 
be done to confirm the role of galectin-3 in regulating FAK and Akt phophorylation 
during LPC proliferation when culturing LPCs on laminin. Nevertheless, these 
results still suggest that galectin-3 may regulate LPC proliferation dependent on the 
cell-adhesion signalling pathway. Furthermore, the expression of CD98 and integrin 
β1 was associated with LPC activation and regulated by galectin-3. In addition, 
CD98 and integrin β1 were both expressed on PanCK positive or galectin-3 positive 
cells, especially on dividing cells, which further suggested that CD98 and integrin β1 
may be involved in regulating LPC proliferation. Further research is needed to assess 
whether galectin-3 in synergy with CD98, activates integrin signalling and regulates 












CHAPTER 6  
 
CONCLUDING REMARKS AND POTENTIAL FUTURE 
STUDIES 
 
In this study, the role of galectin-3 in regulating LPC proliferation and differentiation 
was investigated. I indicated that galectin-3 expression is strongly associated with 
LPC reaction. The essential role of galectin-3 in initiating LPC activation and 
regulating LPC proliferation are demonstrated here by assessing the mouse model of 
LPC induction, the CDE diet. In addition, I demonstrated that galectin-3 is required 
for LPC proliferation and maintaining LPCs in an undifferentiated state on laminin, 
either by investigating primary galectin-3 null primary LPCs or galectin-3 siRNA 
transfected BMOLs. Moreover, I have also shown that the extracellular binding 
activity of galectin-3 is important for LPC adhesion to laminin and LPC proliferation 
in vitro. Furthermore, I indicated that the absence of galectin-3 or the knock down of 
galectin-3 expression down-regulates cyclin D1 but up-regulates p21 and p16. The 
adhesion-mediated signalling pathway such as phosphorylation of FAK and Akt may 
also be involved in this mechanism. Finally, the hypothesis that integrin β1 and 
CD98 are involved in the regulation of LPC behaviour is also proposed.  
 
Laminin has been suggested to play an important role in constituting the LPC niche 
and maintaining LPCs in an undifferentiated state within the niche (Lorenzini et al., 
2010). This study confirmed that laminin can promote LPC proliferation and enhance 
LPC adhesion. In addition, LPCs differentiated into hepatocyte and biliary cells more 
rapidly on plastic plates under conditions which promote differentiation, compared to 
culturing on laminin-coated plates. These data confirm that laminin is essential for 
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LPC proliferation and maintaining LPCs in a less differentiated state.  
 
In vivo, no obvious LPC induction and significantly reduced LPC proliferation was 
observed in the livers of CDE-fed galectin-3 null mice compared to WT controls. In 
addition, galectin-3 was essential in LPC proliferation but has a negative effect on 
LPC differentiation. The absence of galectin-3 leads LPCs to differentiate more 
rapidly on laminin, suggesting that galectin-3 is required to maintain LPCs in an 
undifferentiated state on laminin. These findings also suggested that galectin-3 may 
be crucial in mediating the homeostatic balance between proliferation and 
differentiation of LPCs. For future research, the LPC lineage tracing mice tools can 
be used to investigate whether galectin-3 null mice have a more rapid differentiation 
of LPCs into hepatocytes and biliary cells, compared to the WT mice in vivo. 
Moreover, the in vivo rescue experiment, introducing an adenovirus vector 
expressing galectin-3 (Adv) back to the galectin-3 null mice can also be conducted to 
investigate whether LPC induction can be achieved in the livers of galectin-3 null 
mice by exogenous galectin-3. Furthermore, both WT and galectin-3 null primary 
LPCs can be transplanted into WT mice to investigate whether galectin-3 is 
important for LPCs to repopulate the liver during liver injury. At the converse, WT 
LPCs can be transplanted into both WT and galectin-3 null mice to investigate 
whether the presence of galectin-3 in the supporting environment of the LPC niche is 
crucial for LPC to repopulate the liver during injury.  
 
The apparent co-localisation between galectin-3 expressing cells and the supporting 
cells within the LPC niche: macrophages, was demonstrated. This suggested that 
galectin-3 may itself be involved in cross-talk between LPC and their supporting 
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environment. Galectin-3 may be important in supporting laminin to retain the LPCs 
within the niche for expansion. In this study, galectin-3 null mice fail to form a 
laminin sheaf around LPCs and have less recruitment of macrophages to LPCs, 
suggesting that galectin-3 may play a crucial role in regulating niche formation. 
Galectin-3 is normally strongly expressed by macrophages. Thus the presence of 
galectin-3 in macrophages, one of the supporting cells in the LPC niche, may also 
play an important role in regulating LPC behaviour. Further studies such as in vitro 
co-culture of galectin-3 null macrophages with WT LPCs still need to be conducted 
to analyze whether the absence of galectin-3 in macrophages has an effect on LPC 
proliferation and differentiation.  
 
The importance of galectin-3 in regulating LPC proliferation and differentiation was 
demonstrated here. However the mechanisms by which galectin-3 regulate LPC 
proliferation and differentiation has not been completely investigated. This 
mechanism may be complicated due to the wide distribution of galectin-3 at the cell 
surface, extracellularly and intracellularly. There are two possibilities: (a) 
extracellular galectin-3 may regulate LPC proliferation by mediating LPC adhesion 
to laminin. The essential role of the extracellular binding activity of galectin-3 in 
LPC proliferation and LPC adhesion to laminin was described in this study. Lactose, 
which can block the extracellular binding activity of galectin-3, inhibited LPC 
adhesion to laminin and the growth of LPCs on laminin. (b) Galectin-3 may 
modulate LPC proliferation by regulating the expression of cell cycle regulators. In 
this study, significant down-regulation of cyclin D1 and up-regulation of p16 and p21 
was observed both in galectin-3 null primary cells and galectin-3 siRNA transfected 
BMOLs.  
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Galectin-3 may regulate cyclin D1 expression by regulating the cell-adhesion 
mediated signal pathway or by mediating the enhancement/stabilization of nuclear 
protein-DNA complex formation at the CRE site of the cyclin D1 promoter to 
stimulate cyclin D1 gene expression (Lin et al., 2002). It has been shown that cell 
adhesion signalling is a pre-requisite for growth-induced cyclin D1 expression (Le 
Gall et al., 1998). In addition, the transcription of cyclin D1 is down-regulated 
following the loss of cell adhesion (Zhu et al., 1996). However, it has also been 
demonstrated that galectin-3 induces cyclin D1 promoter activity in human breast 
epithelial cells independent of cell adhesion (Lin et al., 2002). The exact mechanism 
of galectin-3 regulating cyclin D1 expression during LPC proliferation still needs to 
be investigated. Nuclear galectin-3 has been shown to bind to β-catenin which is 
involved in the regulation of Wnt signalling pathway to localize β-catenin to the 
nucleus and stimulate cyclin D1 expression (Shimura et al., 2004). However, the 
down-regulation of β-catenin activation was not observed in galectin-3 null LPCs. 
Further research need to be carried to analyze whether galectin-3 is involved in 
β-catenin activation during LPC proliferation. For example, luciferase reporter 
plasmid containing β-catenin binding sites can be transfected into WT and galectin-3 
nuill LPCs to examine the β-catenin binding activity. 
 
Whether galectin-3 regulates cyclin D1 gene transcription through binding to other 
nuclear protein-DNA complexs remain unclear. Although the down-regulation of 
phosphorylation of FAK and Akt was found in primary galectin-3 null LPCs and 
galectin-3 siRNA transfected BMOLs, this effect was not obvious when the cells 
were cultured on laminin-coated plates. This result may due to the long term culture 
of 4 days since the phosphorylation of FAK and Akt normally occur within 5 min to 
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1 hour. Whether galectin-3 plays an important role in regulating the phosphorylation 
of FAK and Akt during the LPC proliferation on laminin was not completely 
investigated. The recombinant galectin-3 can be introduced to galectin-3 null LPCs 
extracellularly to analyze their short term effects on phosphorylation of FAK and Akt. 
Moreover, whether galectin-3 regulates cyclin D1 expression is dependent on cell 
adhesion remains unknown. For future research, cyclin D1 expression or cyclin D1 
promoter activity of galectin-3 null LPCs which are cultured in suspension can be 
assessed by immunobloting or luciferase assay to examine whether cell adhesion is 
required for regulating cyclin D1 expression. Furthermore, the location of galectin-3 
in proliferating and quiescent LPCs can be examined in future studies since the 
localization of galectin-3 in the cells may be coordinated with the proliferation state. 
 
Finally, CD98 and integrin β1 may also be involved in the regulation of LPC 
behaviour by galectin-3. Galectin-3 has been shown as an endogenous cross-linker of 
CD98 which ligates the glycosylated extracellular domain of CD98, mediating 
integrin clustering on the surface of cells to increase avidity of binding (Hughes et al., 
2001). This mechanism may mediate cell adhesion to laminin. Whether galectin-3 
can trigger CD98 mediated-integrin activation remains unclear. This study has shown 
some preliminary data demonstrating that the expression of CD98 and integrin β1 
were both strongly associated with LPC induction and may be regulated by 
galectin-3. In addition, both CD98 and integrin β1 were expressed on PanCK 
positive LPCs in vitro, especially on proliferating cells. The co-expression of 
galectin-3 and CD98, galectin-3 and integrin β1; CD98 and integrin β1 was also 
observed in LPC culture. Whether CD98 and integrin β1 regulates LPC induction, 
proliferation and differentiation still needs to be investigated. The conditional CD98 
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null mice and integrin β1 deficient mice can be supplemented with CDE diet to 
assess their roles in LPC induction and proliferation in vivo. In addition, BMOLs can 
be transfected with CD98 siRNA or treated with integrin β1 blocking antibody to 
examine their roles in LPC proliferation and differentiation in vitro. Moreover, the 
interactions between CD98 and galectin-3 can be analyzed by immunoprecipitation 
to investigate the interaction between galectin-3 and CD98 of LPCs.  
 
In summary, there are three major findings in my study: (1) Galectin-3 is required to 
maintain LPCs in an undifferentiated state on laminin. (2) Blocking the extracellular 
binding activity of galectin-3 contributes to reduced LPC adhesion to laminin. (3) 
The absence of or the knock-down of galectin-3 expression leads to a cell cycle 
arrest in LPCs. These data proposed that galectin-3 is a key signalling intermediary 
in the LPC niche, regulating homeostatic balance between proliferation and 
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